

CORRECTED
VERSION*

Best Available Copy



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C12N 15/86, A61K 48/00	A1	(11) International Publication Number: WO 98/22609 (43) International Publication Date: 28 May 1998 (28.05.98)
(21) International Application Number: PCT/US97/21494 (22) International Filing Date: 20 November 1997 (20.11.97) (30) Priority Data: 08/752,760 20 November 1996 (20.11.96) US (71) Applicant (for all designated States except US): GENZYME CORPORATION [US/US]; One Mountain Road, Framingham, MA 01701 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): ARMENTANO, Donna, E. [US/US]; 352 Brighon Street, Belmont, MA 02178 (US). GREGORY, Richard, J. [US/US]; 2 Wintergreen Lane, Westford, MA 01866 (US). SMITH, Alan, E. [GB/US]; 1 Mill Street, Dover, MA 02030 (US). (74) Agent: SEIDE, Rochelle, K.; Baker & Botts, LLP, 30 Rockefeller Plaza, New York, NY 10112 (US).		(81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: CHIMERIC ADENOVIRAL VECTORS (57) Abstract A chimeric adenoviral vector is provided that comprises nucleotide sequence of a first adenovirus, wherein all or part of at least one gene of said first adenovirus encoding a protein that facilitates binding of said vector to a target mammalian cell, or internalization thereof within said cell, is replaced by all or part of the corresponding gene from a second adenovirus belonging to subgroup D, said vector further comprising a transgene operably linked to a eucaryotic promoter to allow for expression therefrom in a mammalian cell. Compositions comprising such vectors and methods of using such vectors to deliver transgenes to target mammalian cells, particularly airway epithelial cells, are also provided.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

- 1 -

Description

Chimeric Adenoviral Vectors

5 Introduction

The present invention relates to chimeric adenoviral vectors, that is, vectors comprising DNA from more than one serotype of adenovirus, which offer enhanced infection efficiency of target cells in order to deliver one or more therapeutically useful nucleotide sequences, including transgenes, therein. Such a nucleotide sequence may comprise a gene not otherwise present in the target cell that codes for a therapeutic and/or biologically active protein, or may represent, for example, an active copy of a gene that is already present in the target cell, but in a defective or deficient form.

15 Background of the Invention

One of the fundamental challenges now facing medical practitioners is that although the defective genes that are associated with numerous inherited diseases (or that represent disease risk factors including for various cancers) have been isolated and characterized, methods to correct the disease states themselves by providing patients with normal copies of such genes (the technique of gene therapy) are substantially lacking. Accordingly, the development of improved methods of intracellular delivery therefor is of great medical importance. Examples of diseases that it is hoped can be treated by gene therapy include inherited disorders such as cystic fibrosis, Gaucher's disease, Fabry's disease, and muscular dystrophy.

25 Representative of acquired disorders that can be treated are: (1) for cancers: multiple myeloma, leukemias, melanomas, ovarian carcinoma and small cell lung cancer; (2) for cardiovascular conditions: progressive heart failure, restenosis, and hemophilias; and (3) for neurological conditions: traumatic brain injury.

- 2 -

Gene therapy requires successful transfer of nucleic acid to the target cells of a patient. Gene transfer may generally be defined as the process of introducing an expressible polynucleotide (for example a gene, a cDNA, or an mRNA patterned thereon) into a cell. In a particular application of this approach, successful expression
5 of an encoding polynucleotide leads to production in the cells of a normal protein and leads to correction of a disease state associated with an abnormal gene. Therapies based on providing such proteins directly to target cells (protein replacement therapy) have generally proved ineffective since, for example, the cell membrane presents a selectively permeable barrier to entry. Thus there is great interest in alternative
10 methods to cause delivery of therapeutic proteins, especially by transfer of the relevant polynucleotide, often referred to as a transgene.

Viral vectors have been used with increasing frequency to date to deliver transgenes to target cells. Most attempts to use viral vectors for gene therapy have relied on retrovirus-based vectors, chiefly because of their ability to integrate into the
15 cellular genome. However, the disadvantages of retroviral vectors are becoming increasingly clear, including their tropism for dividing cells only, the possibility of insertional mutagenesis upon integration into the cell genome, decreased expression of the transgene over time, rapid inactivation by serum complement, and the possibility of generation of replication-competent retroviruses. See, for example, D. Jolly, et al.,
20 Cancer Gene Therapy, 1, 1994, pp. 51-64, and C.P. Hodgson, et al., Bio Technology, 13, 1995, pp. 222-225. Such disadvantages have led to the development of other viral-based vector systems, including those derived from adenoviruses.

Adenovirus (Ad) is a nuclear DNA virus with a genome of about 36 kb, which has been well-characterized through studies in classical genetics and molecular
25 biology. A detailed discussion of adenovirus is found in Thomas Shenk, "Adenoviridae and their Replication", and M. S. Horwitz, "Adenoviruses", Chapters 67 and 68, respectively, in Virology, B.N. Fields et al., eds., 2nd edition, Raven Press, Ltd., New York, 1996, and reference therein is found to numerous aspects of adenovirus pathology, epidemiology, structure, replication, genetics and classification.

- 3 -

In a simplified form, the adenoviral genome is classified into early (known as E1-E4) and late (known as L1-L5) transcriptional units, referring to the generation of two temporal classes of viral proteins. The demarcation between these events is viral DNA replication.

5 The human adenoviruses are divided into numerous serotypes (approximately 47, numbered accordingly and classified into 6 subgroups: A, B, C, D, E and F), based upon properties including hemagglutination of red blood cells, oncogenicity, DNA base and protein amino acid compositions and homologies, and antigenic relationships. Additional background information concerning Ad serotype
10 classification, including that for subgroup D, can be found, for example, in F. Deryckere et al., *Journal of Virology*, 70, 1996, pp. 2832-2841; and A. Bailey et al., *Virology*, 205, 1994, pp. 438-452, and in other art-recognized references.

Adenoviruses are nonenveloped, regular icosahedrons (having 20 triangular surfaces and 12 vertices) that are about 65-80 nm in diameter. A protein called fiber
15 projects from each of these vertices. The fiber protein is itself generally composed of 3 identical polypeptide chains, although the length thereof varies between serotypes. The protein coat (capsid) is composed of 252 subunits (capsomeres), of which 240 are hexons, and 12 are pentons. Each penton comprises a penton base, on the surface of the capsid, and a fiber protein projecting from the base. The Ad 2 penton base protein,
20 for example, has been determined to be a 8 x 9 nm ring shaped complex composed of 5 identical protein subunits of 571 amino acids each.

Current understanding of adenovirus-cell interactions suggests that adenovirus utilizes two cellular receptors to attach to, and then infect a target cell. It has been further suggested that the fiber protein of an infecting adenovirus first attaches to a
25 receptor, the identity of which is still unknown, and then penton base attaches to a further receptor, often a protein of the alpha integrin family. It has been determined that alpha-integrins often recognize short amino acid sequences on other cellular proteins for attachment purposes including the tripeptide sequence Arg-Gly-Asp (abbreviated RGD). An RGD sequence is also found in the penton base protein of

- 4 -

adenovirus and is currently understood in the art to mediate attachment of Ad to alpha integrins.

Recombinant adenoviruses have several advantages for use as gene transfer vectors, including tropism for both dividing and non-dividing cells, minimal
5 pathogenic potential, ability to replicate to high titer for preparation of vector stocks, and the potential to carry large inserts (Berkner, K.L., *Curr. Top. Micro. Immunol.* 158:39-66, 1992; Jolly, D., *Cancer Gene Therapy* 1:51-64, 1994).

The carrying capacity of an adenovirus vector is proportional to the size of the adenovirus genome present in the vector. For example, a capacity of about 8 kb can
10 be created from the deletion of certain regions of the virus genome dispensable for virus growth, e.g., E3, and the deletion of a genomic region such as E1 whose function may be restored in trans from 293 cells (Graham, F.L., *J. Gen. Virol.* 36:59-72, 1977) or A549 cells (Imler et al., *Gene Therapy* 3:75-84, 1996). Such E1-deleted vectors are rendered replication-defective, which is desirable for the engineering of adenoviruses
15 for gene transfer. The upper limit of vector DNA capacity for optimal carrying capacity is about 105%-108% of the length of the wild-type genome. Further adenovirus genomic modifications are possible in vector design using cell lines which supply other viral gene products in trans, e.g., complementation of E2a (Zhou et al., *J. Virol.* 70:7030-7038, 1996), complementation of E4 (Krougliak et al., *Hum. Gene Ther.* 6:1575-1586, 1995; Wang et al., *Gene Ther.* 2:775-783, 1995), or
20 complementation of protein IX (Caravokyri et al., *J. Virol.* 69:6627-6633, 1995; Krougliak et al., *Hum. Gene Ther.* 6:1575-1586, 1995). Maximal carrying capacity can be achieved using adenoviral vectors deleted for all viral coding sequences (Kochanek et al., *Proc. Natl. Acad. Sci. USA* 93:5731-5736, 1996; Fisher et al.,
25 *Virology* 217:11-22, 1996).

Transgenes that have been expressed to date by adenoviral vectors include p53 (Wills et al., *Human Gene Therapy* 5:1079-188, 1994); dystrophin (Vincent et al., *Nature Genetics* 5:130-134, 1993; erythropoietin (Descamps et al., *Human Gene Therapy* 5:979-985, 1994; ornithine transcarbamylase (Stratford-Perricaudet et al.,

- 5 -

Human Gene Therapy 1:241-256, 1990; We et al., J. Biol. Chem. 271:3639-3646, 1996;); adenosine deaminase (Mitani et al., Human Gene Therapy 5:941-948, 1994); interleukin-2 (Haddada et al., Human Gene Therapy 4:703-711, 1993); and α 1-antitrypsin (Jaffe et al., Nature Genetics 1:372-378, 1992); thrombopoietin
5 (Ohwada et al., Blood 88:778-784, 1996); and cytosine deaminase (Ohwada et al., Hum. Gene Ther. 7:1567-1576, 1996).

The particular tropism of adenoviruses for cells of the respiratory tract has particular relevance to the use of adenovirus in gene therapy for cystic fibrosis (CF), which is the most common autosomal recessive disease in Caucasians. The disease is
10 caused by the presence of one or more mutations in the gene that encodes a protein known as cystic fibrosis transmembrane conductance regulator (CFTR), and which regulates the movement of ions (and therefore fluid) across the cell membrane of epithelial cells, including lung epithelial cells. Abnormal ion transport in airway cells leads to abnormal mucous secretion, inflammation and infection, tissue damage,
15 and eventually death. Mutations in the CFTR gene that disturb the cAMP-regulated Cl^- channel in airway epithelia result in pulmonary dysfunction (Zabner et al., Nature Genetics 6:75-83, 1994). Adenovirus vectors engineered to carry the CFTR gene have been developed (Rich et al., Human Gene Therapy 4:461-476, 1993) and studies have shown the ability of these vectors to deliver CFTR to nasal epithelia of CF patients
20 (Zabner et al., Cell 75:207-216, 1993), the airway epithelia of cotton rats and primates (Zabner et al., Nature Genetics 6:75-83, 1994), and the respiratory epithelium of CF patients (Crystal et al., Nature Genetics 8:42-51, 1994). Recent studies have shown that administering an adenoviral vector containing a DNA sequence encoding CFTR to airway epithelial cells of CF patients can restore a functioning chloride ion channel
25 in the treated epithelial cells (Zabner et al., J. Clin. Invest. 97:1504-1511, 1996; U.S. Patent No. 5,670,488 issued September 23, 1997).

Serotype classification is partly based on viral surface protein sequence variation. Because the infectious capabilities of the virus are associated with the surface protein interactions of the virus with cellular proteins, the serotype is an

- 6 -

important determinant of viral entry into target cells, and can account for the infectious heterogeneity of adenovirus serotypes. Most adenoviral vectors have been constructed using adenovirus serotypes from the well-studied group C adenoviruses, especially Ad 2 and Ad 5. However, other adenovirus serotypes display infectious
5 properties that are relevant to the further design of improved adenoviral vectors, for example, those derived from subgroup D, which display enhanced tropism for human airway epithelial cells.

It is widely hoped that gene therapy will provide a long lasting and predictable form of therapy for certain disease states, and it is likely the only form of therapy
10 suitable for many inherited diseases. Although adenoviral vectors are currently in clinical use and have shown therapeutic promise, a need remains to improve the infection efficiency of these vectors in order to further improve their gene transfer capabilities. The present invention addresses this goal.

15 Summary Of The Invention

The present invention provides for chimeric adenoviral vectors which offer enhanced infection efficiency of target cells for the delivery of one or more transgenes. In a representative aspect of the invention, the vectors comprise nucleotide sequences coding for therapeutically useful proteins and have enhanced tropism for airway
20 epithelial cells.

Accordingly, there are provided chimeric adenoviral vectors comprising nucleotide sequence of a first adenovirus, wherein at least one gene of said first adenovirus encoding a protein that facilitates binding of said vector to a target mammalian cell, or internalization thereof within said cell, is replaced by the
25 corresponding gene from a second adenovirus belonging to subgroup D. These vectors may further comprising a transgene operably linked to a eucaryotic promoter or other regulatory elements to allow for expression therefrom in a mammalian cell. In a representative aspect thereof, the replaced encoding sequence codes for Ad fiber, hexon or penton base.

- 7 -

In a further preferred embodiment of the invention, there are provided chimeric adenoviral vectors comprising nucleotide sequence of a first adenovirus, wherein a portion of a gene thereof encoding a protein that facilitates binding of said vector to a target mammalian cell, or internalization thereof within said cell, is replaced by a
5 portion of the corresponding gene from a second adenovirus belonging to subgroup D. These vectors may further comprising a transgene operably linked to a eucaryotic promoter or other regulatory elements to allow for expression therefrom in a mammalian cell. In a representative aspect thereof, the replaced encoding sequence codes for a portion of Ad fiber, hexon or penton base.

10 Preferably, the second adenovirus is a member of subgroup D, and the replaced nucleotide sequence encodes a polypeptide selected from the group consisting of Ad fiber, a fragment of Ad fiber, Ad hexon, a fragment of Ad hexon, Ad penton base, and a fragment of Ad penton base. In a preferred embodiment, said second adenovirus is selected from the group consisting of serotypes Ad 9, Ad 15, Ad
15 17, Ad 19, Ad 20, Ad 22, Ad 26, Ad 27, Ad 28, Ad 30, and Ad 39. In preferred embodiments of the chimeric adenoviral vectors, the first adenovirus is selected from the group consisting of Ad 2, Ad 5, and Ad 12.

The invention is also directed to compositions comprising the chimeric adenoviral vectors of the invention. Additional aspects of the invention include
20 methods to use the chimeric adenoviral vectors of the invention to deliver transgenes to mammalian target cells, for example, to the airway epithelial cells of patients.

A still further representative aspect of the invention involves a method of providing a therapeutic and/or biologically active protein to the airway epithelial cells of a patient by administering to said cells an adenoviral vector comprising elements of
25 an Ad 17 genome, and a transgene encoding said therapeutic protein that is operably linked to a eucaryotic promoter to allow for expression therefrom in a mammalian cell, under conditions whereby the transgene encoding said therapeutic protein is expressed, and therapeutic benefit is produced in said airway epithelial cells.

- 8 -

These and other aspects of the present invention are described in the Detailed Description of the Invention which follows directly.

Brief Description of the Drawings

5 FIGURE 1 depicts infection of NHBE cells by Ad 2.

FIGURE 2 depicts infection of NHBE cells by Ad 17.

FIGURE 3 plots the result of binding to human nasal polyp epithelial cell isolates by Ad 2 and Ad 17.

FIGURE 4 is a map of the vector Ad2/ β gal-2/fiber Ad 17.

10 FIGURE 5 shows a comparison of the amino acid sequence of penton base from Ad 17 (top) [SEQ ID NO: 4] and Ad 2 (bottom) [SEQ ID NO: 5], and further depicts the variable RGD containing region.

FIGURE 6 depicts an amino acid sequence pileup for penton base from particular Ad serotypes, including f10 (from fowl) [SEQ ID NO: 6 through SEQ ID
15 NO: 10].

FIGURE 7 shows a comparison of the amino acid sequence of fiber from Ad 17 (top) [SEQ ID NO: 11] and Ad 2 (bottom) [SEQ ID NO: 12].

FIGURE 8 depicts an amino acid sequence pileup for fiber from particular Ad serotypes [SEQ ID NO: 11 through SEQ ID NO: 22], including two forms of serotype
20 40 (40-1 and 40-2) which differ in that one variant has two (but non-identical) copies of the fiber gene.

FIGURE 9 shows the infection efficiency of colon cancer cell lines by adenovirus serotypes.

FIGURE 10 shows the infection efficiency of cancer cell lines by adenovirus
25 serotypes.

Provided in the Sequence Listing attached hereto are also:

SEQ ID NO: 1, the complete nucleotide sequence of Ad 17;

SEQ ID NO: 2, the complete encoding nucleotide sequence for Ad 17 fiber;

- 9 -

SEQ ID NO: 3, the complete encoding nucleotide sequence for Ad 17 penton base.

Detailed Description of the Invention

5 The present invention provides for chimeric adenoviral vectors comprising nucleotide sequence of a first adenovirus, wherein at least one gene of said first adenovirus encoding a protein that facilitates binding of said vector to a target mammalian cell, or internalization thereof within said cell, is replaced by the corresponding gene from a second adenovirus belonging to subgroup D, said vectors
10 further comprising a transgene operably linked to a eucaryotic promoter to allow for expression therefrom in a mammalian cell. In a representative aspect thereof, the replaced encoding sequence correspond to the gene encoding the Ad fiber, hexon or penton base proteins, or combinations thereof.

 In a further preferred embodiment of the invention, there are provided chimeric
15 adenoviral vectors comprising nucleotide sequence of a first adenovirus, wherein a portion of a gene thereof encoding a protein that facilitates binding of said vector to a target mammalian cell, or internalization thereof within said cell, is replaced by a portion of the corresponding gene from a second adenovirus belonging to subgroup D, said vectors further comprising a transgene operably linked to a eucaryotic promoter to
20 allow for expression therefrom in a mammalian cell. In a representative aspect thereof, the replaced encoding sequence codes for a portion of the Ad fiber, hexon or penton base proteins, or combinations thereof. Where a portion of a gene from a second adenovirus is used to construct a chimeric adenoviral vector, such sequence will have a length sufficient to confer a desired serotypic-specific virus-cell interaction to the
25 vector.

 The present invention involves the recognition that adenoviral vectors that are either based substantially upon the genome of Ad serotypes classified in subgroup D, or that contain certain Ad-protein encoding polynucleotide sequences of subgroup D adenovirus, are particularly effective at binding to, and internalizing within, human

- 10 -

cells, such that therapeutic transgenes included in the adenoviral vector are efficiently expressed. This discovery is particularly surprising given that adenovirus serotypes of subgroup D are not clinically associated with human respiratory disease, and that, for example association with conjunctivitis is more typical. The recognition of this

5 tropism is of particular relevance for the treatment by gene therapy of recognized disease states such as cystic fibrosis or α 1-antitrypsin deficiency. This discovery is particularly surprising given that adenovirus serotypes of subgroup D are not clinically associated with human respiratory disease, and that, for example association with conjunctivitis is more typical. The recognition of this tropism is of particular relevance

10 for the treatment by gene therapy of recognized disease states such as cystic fibrosis or α 1-antitrypsin deficiency.

In a representative aspect of the invention, the adenoviral vectors further comprise nucleotide sequences coding for one or more transgenes and have enhanced tropism for airway epithelial cells. Preferably, the chimeric adenoviral vectors are

15 replication-defective, a feature which contributes to the enhanced safety of adenoviral vectors administered to individuals.

Preferably, the second adenovirus is a member of subgroup D, and the replaced nucleotide sequence encodes a polypeptide selected from the group consisting of Ad fiber, a fragment of Ad fiber, Ad hexon, a fragment of Ad hexon, Ad penton base, and

20 a fragment of Ad penton base. In a preferred embodiment, said second adenovirus is selected from the group consisting of serotypes Ad 9, Ad 15, Ad 17, Ad 19, Ad 20, Ad 22, Ad 26, Ad 27, Ad 28, Ad 30, and Ad 39. In a most preferred embodiment, the second adenovirus is Ad 17. In other preferred embodiments of the chimeric adenoviral vectors, the first adenovirus is selected from the group consisting of Ad 2,

25 Ad 5, and Ad 12.

There is substantial evidence that any reported transforming properties of the E4 region of certain subgroup D serotypes do not extend to Ad serotypes whose use is preferred according to the practice of the present invention (see, for example, R. Javier

- 11 -

et al., Science, 257, 1992, pp. 1267-1271). It is expected also that, for example, individual ORFs of subgroup D E4 region, such as ORF1, could be deleted.

Additional aspects of the invention include methods to provide biologically active and/or therapeutic proteins to mammalian cells, including, but not limited to, the airway epithelial cells of individuals, in order to provide phenotypic benefit. According to this aspect of the invention, chimeric adenoviral vectors are used in which a nucleotide sequence of a first adenovirus is replaced by the corresponding nucleotide sequence of a second adenovirus. Preferably, the second adenovirus is a member of subgroup D, and the replaced nucleotide sequence encodes a polypeptide encoding all or part of Ad fiber, Ad hexon, or Ad penton base, or combinations thereof.

A still further representative aspect of the invention involves providing a biologically active and/or therapeutic protein in the airway epithelial cells of a patient by administering to said cells an adenoviral vector comprising elements of an Ad 17 genome, and a transgene encoding said protein that is operably linked to a eucaryotic promoter to allow for expression therefrom in a mammalian cell, under conditions whereby the transgene encoding said protein is expressed, and the desired phenotypic benefit is produced in said airway epithelial cells. According to the practice of the invention, it is preferred that an chimeric adenovirus vector utilized to deliver a transgene to the respiratory epithelium (including that of the nasal airway, trachea, and bronchi and alveoli of the lung), or to other tissues of the body, comprise serotypes within subgroup D, as such classification is recognized in the art.

In order to construct the chimeric adenoviral vectors of the invention, reference may be made to the substantial body of literature on how such vectors may be designed, constructed and propagated using techniques from molecular biology and microbiology that are well-known to the skilled artisan. Specific examples of adenoviral vector genomes which can be used as the backbone for a chimeric adenoviral vector of the invention include, for example, Ad2/CFTR-1 and Ad2/CFTR-2 and others described in U. S. Patent No. 5,670,488, issued September 23, 1997

- 12 -

(incorporated herein by reference). Such vectors may include deletion of the E1 region, partial or complete deletion of the E4 region, and deletions within, for example, the E2 and E3 regions. Within the scope of the invention are, for example, chimeric vectors which contain an Ad 2 backbone with one or more Ad 17 capsid proteins or fragments thereof in the virus. Other adenoviral vector genomic designs which can be used in the chimeric adenoviral vectors of the invention include those derived from allowed U.S. Patent Application Serial No. 08/409,874, filed March 24, 1995, and allowed U.S. Patent Application Serial No. 08/540,077, filed October 6, 1995 (both incorporated herein by reference).

To construct the recombinant chimeric adenoviral vectors of the invention which contain a transcription unit, the skilled artisan can use the standard techniques of molecular biology to engineer a transgene or a capsid protein into a backbone vector genome (Berkner, K.L., Curr. Top. Micro. Immunol. 158:39-66, 1992). For example, a plasmid containing a transgene and any operably linked regulatory elements inserted into an adenovirus genomic fragment can be co-transfected with a linearized viral genome derived from an adenoviral vector of interest into a recipient cell under conditions whereby homologous recombination occurs between the genomic fragment and the virus. Preferably, a transgene is engineered into the site of an E1 deletion. As a result, the transgene is inserted into the adenoviral genome at the site in which it was cloned into the plasmid, creating a recombinant adenoviral vector. The chimeric adenoviral vectors can also be constructed using standard ligation techniques, for example, removing a restriction fragment containing a fiber gene from a first adenovirus and ligating into that site a restriction fragment containing a fiber gene from a second adenovirus. A representative example of a chimeric adenoviral vector of the invention is Ad2/ β gal-2 fiber 17 (exemplified in Example 6).

Construction of the chimeric adenoviral vectors can be based on adenovirus DNA sequence information widely available in the field, e.g., nucleic acid sequence databases such as GenBank.

- 13 -

Preparation of replication-defective chimeric adenoviral vector stocks can be accomplished using cell lines that complement viral genes deleted from the vector, e.g., 293 or A549 cells containing the deleted adenovirus E1 genomic sequences. The use of HER3 cells (human embryonic retinoblasts transformed by Ad 12), as a
5 complementing cell line is of note. After amplification of plaques in suitable complementing cell lines, the viruses can be recovered by freeze-thawing and subsequently purified using cesium chloride centrifugation. Alternatively, virus purification can be performed using chromatographic techniques, e.g., as set forth in International Application No. PCT/US96/13872, filed August 30, 1996, incorporated
10 herein by reference.

Titers of replication-defective chimeric adenoviral vector stocks can be determined by plaque formation in a complementing cell line, e.g., 293 cells. End-point dilution using an antibody to the adenoviral hexon protein may be used to quantitate virus production or infection efficiency of target cells (Armentano et al.,
15 Hum. Gene Ther. 6:1343-1353, 1995, incorporated herein by reference).

Transgenes which can be delivered and expressed from a chimeric adenoviral vector of the invention include, but are not limited to, those encoding enzymes, blood derivatives, hormones, lymphokines such as the interleukins and interferons, coagulants, growth factors, neurotransmitters, tumor suppressors, apolipoproteins,
20 antigens, and antibodies, and other biologically active proteins. Specific transgenes which may be encoded by the chimeric adenoviral vectors of the invention include, but are not limited to, cystic fibrosis transmembrane regulator (CFTR), dystrophin, glucocerebrosidase, tumor necrosis factor, p53, p21, herpes simplex thymidine kinase and gancyclovir, retinoblastoma (Rb), and adenosine deaminase (ADA). Transgenes
25 encoding antisense molecules or ribozymes are also within the scope of the invention. The vectors may contain one or more transgenes under the control of one or more regulatory elements.

In addition to containing the DNA sequences encoding one or more transgenes, the chimeric adenoviral vectors of the invention may contain any

- 14 -

expression control sequences such as a promoter or enhancer, a polyadenylation element, and any other regulatory elements that may be used to modulate or increase expression, all of which are operably linked in order to allow expression of the transgene. The use of any expression control sequences, or regulatory elements,
5 which facilitate expression of the transgene is within the scope of the invention. Such sequences or elements may be capable of generating tissue-specific expression or be susceptible to induction by exogenous agents or stimuli.

Infection of target cell by the chimeric adenoviral vectors of the invention may also be facilitated by the use of cationic molecules, such as cationic lipids as disclosed
10 in PCT Publication No. WO96/18372, published June 20, 1996, incorporated herein by reference.

Cationic amphiphiles have a chemical structure which encompasses both polar and non-polar domains so that the molecule can simultaneously facilitate entry across a lipid membrane with its non-polar domain while its cationic polar domain attaches
15 to a biologically useful molecule to be transported across the membrane.

Cationic amphiphiles which may be used to form complexes with the chimeric adenoviral vectors of the invention include, but are not limited to, cationic lipids, such as DOTMA (Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413-7417, 1987) (N-[1-(2,3-dioletoxy)propyl]-N,N,N - trimethylammonium chloride); DOGS
20 (dioctadecylamidoglycylspermine) (Behr et al., Proc. Natl. Acad. Sci. USA 86:6982-6986, 1989); DMRIE (1,2-dimyristyloxypropyl-3-dimethyl-hydroxyethyl ammonium bromide) (Felgner et al., J. Biol. Chem. 269:2550-2561, 1994; and DC-chol (3B [N-N', N'-dimethylaminoethane) -carbamoyl] cholesterol) (U.S. Patent No. 5, 283,185 to Epand et al.). The use of other cationic amphiphiles recognized in the art or which
25 come to be discovered is within the scope of the invention.

In preferred embodiments of the invention, the cationic amphiphiles useful to complex with and facilitate transfer of the vectors of the invention are those lipids which are described in PCT Publication No. WO96/18372, published June 20, 1996, which is incorporated herein by reference. Preferred cationic amphiphiles described

- 15 -

herein to be used in the delivery of the plasmids and/or viruses are GL-53, GL-67, GL-75, GL-87, GL-89, and GL-120, including protonated, partially protonated, and deprotonated forms thereof. Further embodiments include the use of non-T-shaped amphiphiles as described on pp. 22-23 of the aforementioned PCT application, 5 including protonated, partially protonated and deprotonated forms thereof. Most preferably, the cationic amphiphile which can be used to deliver the vectors of the invention is spermine cholesterol carbamate (GL-67).

In the formulation of compositions comprising the chimeric adenoviral vectors of the invention, one or more cationic amphiphiles may be formulated with neutral co- 10 lipids such as dileoylphosphatidylethanolamine (DOPE) to facilitate delivery of the vectors into a cell. Other co-lipids which may be used in these complexes include, but are not limited to, diphytanoylphosphatidylethanolamine, lyso-phosphatidylethanolamines, other phosphatidylethanolamines, phosphatidylcholines, lyso-phosphatidylcholines and cholesterol. A preferred molar ratio of cationic 15 amphiphile to colipid is 1:1. However, it is within the scope of the invention to vary this ratio, including also over a considerable range. In a preferred embodiment of the invention, the cationic amphiphile GL-67 and the neutral co-lipid DOPE are combined in a 1:2 molar ratio, respectively, before complexing with a chimeric adenoviral vector for delivery to a cell.

20 In the formulation of complexes containing a cationic amphiphile with a chimeric adenoviral vector, a preferred range of 10^7 - 10^{10} infectious units of virus may be combined with a range of 10^4 - 10^6 cationic amphiphile molecules/viral particle.

The infection efficiency of the chimeric adenoviral vectors of the invention 25 may be assayed by standard techniques to determine the infection of target cells. Such methods include, but are not limited to, plaque formation, end-point dilution using, for example, an antibody to the adenoviral hexon protein, and cell binding assays using radiolabelled virus. Improved infection efficiency may be characterized as an increase in infection of at least an order of magnitude with reference to a control virus. Where

- 16 -

a chimeric adenoviral vector encodes a marker or other transgene, relevant molecular assays to determine expression include the measurement of transgene mRNA, by, for example, Northern blot, S1 analysis or reverse transcription-polymerase chain reaction (RT-PCR). The presence of a protein encoded by a transgene may be detected by

5 Western blot, immunoprecipitation, immunocytochemistry, or other techniques known to those skilled in the art. Marker-specific assays can also be used, such as X-gal staining of cells infected with a chimeric adenoviral vector encoding β -galactosidase.

In order to determine transgene expression and infection efficiency in vivo using the constructs and compositions of the invention, animal models may be

10 particularly relevant in order to assess transgene persistence against a background of potential host immune response. Such a model may be chosen with reference to such parameters as ease of delivery, identity of transgene, relevant molecular assays, and assessment of clinical status. Where the transgene encodes a protein whose lack is associated with a particular disease state, an animal model which is representative of

15 the disease state may optimally be used in order to assess a specific phenotypic result and clinical improvement. However, it is also possible that particular chimeric adenoviral vectors of the invention display enhanced infection efficiency only in human model systems, e.g., using primary cell cultures, tissue explants, or permanent cell lines. In such circumstances where there is no animal model system available in

20 which to model the infection efficiency of a chimeric adenoviral vector with respect to human cells, reference to art-recognized human cell culture models will be most relevant and definitive.

Relevant animals in which the chimeric adenoviral vectors may be assayed include, but are not limited to, mice, rats, monkeys, and rabbits. Suitable mouse

25 strains in which the vectors may be tested include, but are not limited to, C3H, C57Bl/6 (wild-type and nude) and Balb/c (available from Taconic Farms, Germantown, New York).

Where it is desirable to assess the host immune response to vector administration, testing in immune-competent and immune-deficient animals may be

- 17 -

compared in order to define specific adverse responses generated by the immune system. The use of immune-deficient animals, e.g., nude mice, may be used to characterize vector performance and persistence of transgene expression, independent of an acquired host response.

5 In a particular embodiment where the transgene is the gene encoding cystic fibrosis transmembrane regulator protein (CFTR) which is administered to the respiratory epithelium of test animals, expression of CFTR may be assayed in the lungs of relevant animal models, for example, C57Bl/6 or Balb/c mice, cotton rats, or Rhesus monkeys. Molecular markers which may be used to determine expression
10 include the measurement of CFTR mRNA, by, for example, Northern blot, S1 analysis or RT-PCR. The presence of the CFTR protein may be detected by Western blot, immunoprecipitation, immunocytochemistry, or other techniques known to those skilled in the art. Such assays may also be used in tissue culture where cells deficient in a functional CFTR protein and into which the chimeric adenoviral vectors have
15 been introduced may be assessed to determine the presence of functional chloride ion channels - indicative of the presence of a functional CFTR molecule.

 The chimeric adenoviral vectors of the invention have a number of in vivo and in vitro utilities. The vectors can be used to transfer a normal copy of a transgene encoding a biologically active protein to target cells in order to remedy a deficient or
20 dysfunctional protein. The vectors can be used to transfer marked transgenes (e.g., containing nucleotide alterations) which allow for distinguishing expression levels of a transduced gene from the levels of an endogenous gene. The chimeric adenoviral vectors can also be used to define the mechanism of specific viral protein-cellular protein interactions that are mediated by specific virus surface protein sequences. The
25 vectors can also be used to optimize infection efficiency of specific target cells by adenoviral vectors, for example, using a chimeric adenoviral vector containing Ad 17 fiber protein to infect human nasal polyp cells. Where it is desirable to use an adenoviral vector for gene transfer to cancer cells in an individual, a chimeric adenoviral vector can be chosen which selectively infects the specific type of target

- 18 -

cancer cell and avoids promiscuous infection. Where primary cells are isolated from a tumor in an individual requiring gene transfer, the cells may be tested against a panel of chimeric adenoviral vectors to select a vector with optimal infection efficiency for gene delivery. The vectors can further be used to transfer tumor antigens to dendritic
5 cells which can then be delivered to an individual to elicit an anti-tumor immune response. Chimeric adenoviral vectors can also be used to evade undesirable immune responses to particular adenovirus serotypes which compromise the gene transfer capability of adenoviral vectors.

The present invention is further directed to compositions containing the
10 chimeric adenoviral vectors of the invention which can be administered in an amount effective to deliver one or more desired transgenes to the cells of an individual in need of such molecules and cause expression of a transgene encoding a biologically active protein to achieve a specific phenotypic result. The cationic amphiphile-plasmid complexes or cationic amphiphile-virus complexes may be formulated into
15 compositions for administration to an individual in need of the delivery of the transgenes.

The compositions can include physiologically acceptable carriers, including any relevant solvents. As used herein, "physiologically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents,
20 isotonic and absorption delaying agents, and the like. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the compositions is contemplated.

Routes of administration for the compositions containing the chimeric adenoviral vectors of the invention include conventional and physiologically
25 acceptable routes such as direct delivery to a target organ or tissue, intranasal, intravenous, intramuscular, subcutaneous, intradermal, oral and other parenteral routes of administration.

The invention is further directed to methods for using the compositions of the invention in vivo or ex vivo applications in which it is desirable to deliver one or more

- 19 -

transgenes into cells such that the transgene produces a biologically active protein for a normal biological or phenotypic effect. In vivo applications involve the direct administration of one or more chimeric adenoviral vectors formulated into a composition to the cells of an individual. Ex vivo applications involve the transfer of
5 a composition containing the chimeric adenoviral vectors directly to autologous cells which are maintained in vitro, followed by readministration of the transduced cells to a recipient.

Dosage of the chimeric adenoviral vector to be administered to an individual for expression of a transgene encoding a biologically active protein and to achieve a
10 specific phenotypic result is determined with reference to various parameters, including the condition to be treated, the age, weight and clinical status of the individual, and the particular molecular defect requiring the provision of a biologically active protein. The dosage is preferably chosen so that administration causes a specific phenotypic result, as measured by molecular assays or clinical markers. For
15 example, determination of the infection efficiency of a chimeric adenoviral vector containing the CFTR transgene which is administered to an individual can be performed by molecular assays including the measurement of CFTR mRNA, by, for example, Northern blot, S1 or RT-PCR analysis or the measurement of the CFTR protein as detected by Western blot, immunoprecipitation, immunocytochemistry, or
20 other techniques known to those skilled in the art. Relevant clinical studies which could be used to assess phenotypic results from delivery of the CFTR transgene include PFT assessment of lung function and radiological evaluation of the lung. Demonstration of the delivery of a transgene encoding CFTR can also be demonstrated by detecting the presence of a functional chloride channel in cells of an
25 individual with cystic fibrosis to whom the vector containing the transgene has been administered (Zabner et al., J. Clin. Invest. 97:1504-1511, 1996). Transgene expression in other disease states can be assayed analogously, using the specific clinical parameters most relevant to the condition.

- 20 -

Dosages of a chimeric adenoviral vector which are effective to provide expression of a transgene encoding a biologically active protein and achieve a specific phenotypic result range from approximately 10^8 infectious units (I.U.) to 10^{11} I.U. for humans.

5 It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subjects to be treated, each unit containing a predetermined quantity of active ingredient calculated to produce the specific phenotypic effect in association with the required
10 physiologically acceptable carrier. The specification for the novel dosage unit forms of the invention are dictated by and directly depend on the unique characteristics of the chimeric adenoviral vector and the limitations inherent in the art of compounding. The principal active ingredient (the chimeric adenoviral vector) is compounded for convenient and effective administration in effective amounts with the physiologically
15 acceptable carrier in dosage unit form as discussed above.

Maximum benefit and achievement of a specific phenotypic result from administration of the chimeric adenoviral vectors of the invention may require repeated administration. Such repeated administration may involve the use of the same chimeric adenoviral vector, or, alternatively, may involve the use of different
20 chimeric adenoviral vectors which are rotated in order to alter viral antigen expression and decrease host immune response.

The practice of the invention employs, unless otherwise indicated, conventional techniques of protein chemistry, molecular virology, microbiology, recombinant DNA technology, and pharmacology, which are within the skill of the
25 art. Such techniques are explained fully in the literature. See, e.g., Current Protocols in Molecular Biology, Ausubel et al., eds., John Wiley & Sons, Inc., New York, 1995, and Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Co., Easton, PA, 1985.

- 21 -

The invention is further illustrated by the following specific examples which are not intended in any way to limit the scope of the invention.

Examples

5

Example 1 Infection of NHBE cells by adenovirus serotypes of subgroup D

Normal human bronchial epithelial ("NHBE") cells were obtained from Clonetics (San Diego, CA), and plated on Costar (Cambridge, MA) Transwell-Clear polyester membranes that were pre-coated with human placental collagen. The wells
10 were placed in a cluster plate and cells were fed every day for one week by changing the medium in both the well and the plate. After one week the media was removed from the wells to create an air-liquid interface, and the cells were then fed only by changing the medium in the cluster plate, every other day for one week. Cells were infected at an moi of 1 by adding virus (see below) to the transwell, followed by an
15 incubation time of 1.5-2 hours. At the end of the incubation period, the medium was removed and the cells were gently rinsed with fresh medium. Thirty-six hours post-infection the cells were fixed with 1:1 acetone:methanol, permeablized with a solution of 0.05% Tween 20 in PBS, and stained with FITC labeled anti-hexon antibody (Chemicon, Temecula, CA) to visualize cells that had been productively infected (i.e.
20 to visualize virus replication). Cells were also subjected to the DAPI staining procedure in order to visualize the total number of nuclei. The results could be readily determined upon simple inspection.

Wild type Ad serotypes within subgroup D that were tested included 9, 15, 17, 19, 20, 22, 26, 27, 28, 30, and 39 (all from the American Type Culture Collection,
25 Rockville, MD). An Ad 2 (obtained as DNA from BRL, Gaithersburg, MD, and used to transfect 293 cells in order to generate virus stock) was used as a control. Infection observed with all of the subgroup D serotypes was superior to that observed with Ad 2, with the best results being achieved with Ad 9, Ad 17, Ad 20, Ad 22, and Ad 30.

- 22 -

Additionally, it was determined that each of the above-mentioned serotypes of subgroup D was more effective in the NHBE cell assay under similar circumstances than any other serotype tested than belongs to a subgroup other than D. In this regard, the following serotypes were also tested: 31(subgroup A); 3(subgroup B); 7(subgroup B); 7a(subgroup B); 14(subgroup B); 4(subgroup E); and 41(subgroup F). In a further experiment, serotype 35 (subgroup A) may have performed as well as the least effective members of subgroup D that were tested.

Example 2 Infection of clinical isolate bronchial epithelial cells

Following generally the procedures of Example 1, human bronchial epithelial cells recovered from healthy human volunteers were infected with either Ad 2 (as above, Ad 2 DNA was obtained from BRL, and this DNA was used to transfect 293 cells to generate virus) (Figure 1), or Ad 17 (from ATCC) (Figure 2), all at an moi of 50. Cells were left in contact with virus for 30 minutes, 3 hours, or 12 hours.

The increased tropism of Ad 17 for human bronchial epithelial cells, compared with Ad 2, is readily apparent upon inspection of Figures 1 and 2. In the Figures, the right hand columns (panels D, E, and F, stained in blue) show total numbers of cells present (from DAPI staining as above), whereas the left hand columns (panels A, B, and C, stained in green) quantify adenovirus hexon protein present in the infected cells (from FITC-labeled anti-hexon antibody, as above). Panels A and D result from 30 minute incubation times, panels B and E result from 3 hour incubation times, and panels C and F result from 12 hour incubation times. As measured by the technique employed, infection of airway epithelia by Ad 17 is at least 50 fold greater than by Ad 2 for the thirty minute incubation time.

25

Example 3 Binding of Ad 2 and Ad 17 to human nasal polyp cell isolates

293 cells, a complementing cell line developed by Graham et al. (see Gen. Virol., 36, 1977, pp. 59-72), were infected with either wild type Ad 2 or wild type Ad 17. Five hours post-infection the media was removed and replaced with methionine

- 23 -

free media containing S^{35} metabolic label (Amersham). After an additional six hours, fresh media was added and the labeling was allowed to proceed for a total of 18 hours, after which the S^{35} media was removed and replaced with fresh media. Thirty hours post-infection the cells were harvested and lysed and the labeled Ad 2 or Ad 17
5 viruses were purified by CsCl gradient centrifugation. The recovered viruses were then used in an assay to determine their relative binding efficiency on human nasal polyp cells.

In order to perform the assay, ciliated human airway epithelial cells were recovered from nasal polyps of healthy volunteers. The results from two such isolates,
10 NP-14 and NP-15, are reported here (see Figure 3). Radiolabeled virus was then incubated with the isolated cells in wells for specified times (5 or 30 minutes, see Figure 3). The cells were then rinsed and measured for radioactivity. Binding as reported in Figure 3 indicates the percent of input radioactivity that is cell associated. It was determined that for both cell isolate populations, using either 5 or 30 minute
15 incubations, cell associated radioactivity was 10-fold enhanced if Ad 17 rather than Ad 2 was used.

Example 4 Fiber competition

20 A549 cells (a human lung carcinoma line, obtained from the American Type Culture Collection as ATCC CCL-185) were plated at 3×10^4 cells per well in 96-well dishes. Since the number of receptor sites for adenovirus fiber on the cell surface has been estimated to be approximately 10^5 receptors per cell, the receptors in the plated cells were saturated, in this example, with $0.1 \mu\text{g}$ of purified full length Ad 2 fiber
25 protein (obtained from Paul Freimuth, Brookhaven National Laboratory, Upton, NY), which corresponds to approximately 100 molecules of fiber per receptor. Cells were incubated with Ad 2 fiber in PBS for two hours at 37°C .

- 24 -

The cells were subsequently infected at an moi of 1 (using either Ad 2 provided as above, or wild type Ad 17) for one hour, after which the cells were rinsed, and fresh medium was added. Control cultures were incubated with PBS with no added protein for two hours and then subsequently infected as described above. Forty
5 hours post-infection the cells were fixed with 1:1 acetone:methanol, permeabilized with 0.05% Tween 20 in PBS and stained with FITC labeled anti- Ad 2 hexon antibody, as described in Example 1. As determined by this assay, the number of cells infected (stained) with Ad 2 was reduced by approximately 90% in cultures that were pre-incubated with Ad 2 fiber as compared to control cultures. However, no effect on
10 Ad 17 infection was observed by the pre-incubation of A549 cells with full length Ad 2 fiber.

Example 5 Use of Ad 2 fiber knob in a binding competition
experiment with Ad 2

15

Further competition experiments were performed with Ad 2 and Ad 17 fiber knobs that had been expressed and purified from *E. coli*. DNA sequences encoding both protein fragments were designed so that the fiber knobs expressed therefrom would contain histidine tags in order to permit nickel- column purification. The yield
20 of soluble fiber knob trimer, purified by the Ni-NTA method (Qiagen, Chatsworth, CA), was ~25µg/50ml culture. A significant portion of the total knob protein expressed appeared to remain in a monomeric (and insoluble) form. The soluble trimeric material obtained was used for a preliminary competition experiment. Wild type Ad 2 and Ad 17 were used to infect A549 cells, or cells that had been pre-
25 incubated with excess (about 100 molecules of trimer per receptor) Ad 2 fiber knob or Ad 17 fiber knob. The results indicated that Ad 2 fiber knob, but not Ad 17 knob, could block Ad 2 infection. Additionally, Ad 17 infection was not blocked by *E. coli*-expressed fiber knobs of either serotype, suggesting that the mechanism of Ad 2 and Ad 17 infections is different.

- 25 -

Example 6 Construction of the chimeric vector Ad2/ β gal-2/fiber Ad 17

The vector Ad2/ β gal-2 was constructed as follows. A CMV β gal expression
5 cassette was constructed in a pBR322-based plasmid that contained Ad 2 nucleotides
1-10,680 from which nucleotides 357-3328 were deleted. The deleted sequences were
replaced with (reading from 5' to 3'): a cytomegalovirus immediate early promoter
(obtained from pRC/CMV, Invitrogen), lacZ gene encoding β -galactosidase with a
nuclear localization signal, and an SV40 polyadenylation signal (nucleotides 2533-
10 2729). The resulting plasmid was used to generate Ad2/ β gal-2 by recombination with
Ad2E4ORF6 (D. Armentano et al., Human Gene Therapy , 6, 1995, pp 1343 -1353).

A chimeric Ad2/ β gal-2/fiber Ad 17 viral vector (Figure 4) was then constructed
as follows. pAdORF6 (D. Armentano et al., Human Gene Therapy , 6, 1995, pp 1343
-1353 was cut with Nde and BamHI to remove Ad 2 fiber coding and polyadenylation
15 signal sequences (nucleotides 20624-32815). An NdeI-BamHI fragment containing
Ad 17 fiber coding sequence (nucleotides 30984-32095) was generated by PCR and
ligated along with an SV40 polyadenylation signal into NdeI-BamHI cut pAdORF6 to
generate pAdORF6fiber17. This plasmid was cut with PacI and then ligated to PacI-
cut Ad2/ β gal-2 DNA to generate Ad2/ β gal-2fiber 17. Any desired transgene may be
20 substituted in this construct for the reporter gene.

A similar construct can be prepared using a DNA sequence that encodes Ad 17
penton base instead of Ad 17 fiber. Alternatively, only a subregion of the penton base
of Ad 2 need be subject to replacement, such as by inserting into the vector a
nucleotide encoding sequence corresponding to any amino acid subsequence of Ad 17
25 penton base amino acids 283-348 (see the marked sequence in Figure 5A) in
replacement for any subsequence of Ad 2 penton base amino acids 290-403.
Preferably, the replaced sequence of Ad 2 and the inserted sequence of Ad 17
includes the RGD domain of each. Use of nucleotide sequence corresponding to
penton base amino acid sequence for other subgroup D serotypes is also within the

- 26 -

practice of the invention. It is also within the scope of the invention to replace a subregion of the fiber protein in the Ad 2 vector with a subregion from another adenovirus serotype, for example, Ad 17.

- 5 Example 7 Ad2/ β gal-2f17 shows increased infection efficiency on human airway explants

Both human and monkey trachea explants, about 1 cm², were placed on top of an agar support. Each explant was infected at an moi of 200 of either Ad2/ β gal-2 or Ad2/ β gal-2f17 assuming a cell density of 1 x 10⁶ per cm² of explant. Explants were
10 exposed to virus for three hours and were then rinsed with NHBE media. Two days post-infection explants were stained with X-gal and infection efficiency was assessed. On the monkey explants Ad2/ β gal-2 gave rise to a higher infection efficiency than Ad2/ β gal-2f17. Patches of stained cells were detected in explants exposed to Ad2/ β gal-2 but very few cells stained in explants exposed to Ad2/ β gal-2f17. A
15 different result was obtained on human trachea explants. On these explants Ad2/ β gal-2f17 infection gave rise to a much higher infection efficiency than Ad2/ β gal-2 infection. Approximately 5-10% of the cells in explants exposed to Ad2/ β gal-2f17 stained with X-gal whereas very few cells were stained in explants exposed to Ad2/ β gal-2. No background staining was observed in either monkey or human
20 explants that were not exposed to virus.

The results indicate that the exchange of Ad 2 fiber for Ad 17 fiber in Ad2/ β gal-2f17 was sufficient to significantly increase infection efficiency of human tracheal airway cells by an adenovirus type 2 based vector.

- 25 Example 8 Adenovirus subgroup screening on human cancer cell lines

Identification of adenovirus subgroup that best infects a particular tumor type may be useful in designing vectors to optimally target cancer cells in vivo. In order to determine the adenovirus subgroup that best infects a particular type of cancer cell, cancer cells were seeded into a 96 well plate and infected with and moi of 5. Infection

- 27 -

efficiency was determined by staining of infected cells using an anti-hexon antibody. The adenovirus subgroups were represented by the following serotypes: A: Ad 31; B: Ad 3; C: Ad 2; D: Ad 17; E: Ad 4; and F: Ad 41.

Subgroup D (Ad 17) has a significantly higher infection rate of the colon
5 cancer cell line CaCo-2 than other cell types, with an infection rate of 70%, while Ad 2 only infected 20% of the cells (Figure 9).

Subgroup D (Ad 17) was effective in infecting ovarian cancer cell line SK-OV3. Infection was measured at 90% (Figure 10).

10 Sequence Listing

Included herewith on the following pages are informal copies of SEQ ID NO: 1 through SEQ ID NO: 3.

1 CATCATCAAT AATATACCCC ACAAAGTAAA CAAAAGTTAA TATGCAAATG AGGTTTAAAA
 61 TTTAGGGCGG GGCTACTGCT GATTGGCCGA GAAACGTTGA TGCAAATGAC GTCACGACGC
 121 ACGGCTAACG GTCGCCCGG AGGCGTGGCC TAGCCCGGAA GCAAGTCGCG GGGCTGATGA
 181 CGTATAAAAA AGCGGACTTT AAACCCGGAA ACGGCCGATT TTCCCGCGGC CACGCCCGGA
 241 TATGAGGTAA TTCTGGGCGG ATGCAAGTGA AATTAGGTCA TTTTGGCGCG AAAACTGAAT
 301 GAGGAAGTGA AAAGTGAAAA ATACCGGTCC CGCCAGGGC GGAATATTTA CCGAGGGCCG
 361 AGAGACTTTG ACCGATTACG TGTGGGTTTC GATTGCGGTG TTTTTCGCG AATTTCGCG
 421 TCCGTGTCAA AGTCCGGTGT TTATGTCACA GATCAGCTGA TCCACAGGGT ATTTAAACCA
 481 GTCGAGCCCG TCAAGAGGCC ACTCTTGAGT GCCAGCGAGT AGAGATTTCT CTGAGCTCCG
 541 CTCCCAGAGT GTGAGAAAAA TGAGACACCT GCGCCTCCTG CCTGGAAGTG TGCCCTTGGA
 601 CATGGCCGCA TTATTGCTGG ATGACTTTGT GAGTACAGTA TTGGAGGATG AACTGCAACC
 661 AACTCCGTTT GAGCTGGGAC CCACACTTCA GGACCTCTAT GATTTGAGG TAGATGCCCA
 721 GGAGGACGAC CCGAACGAAG ATGCTGTGAA TTTAATATTT CCAGAATCTC TGATCTTTCA
 781 GGCTGACATA GCCAGCGAAG CTCTACCTAC TCCACTTCAT ACTCCAATC TGTCACCCAT
 841 ACCTGAATTG GAAGAGGAGG ACGAGTTAGA CCTCCGGTGT TATGAGGAAG GTTTTCCTCC
 901 CAGCGATTCA GAGGACGAAC AGGGTGAGCA GAGCATGGCT CTAATCTCAG ACTATGCTTG
 961 TGTGGTTGTG GAAGAGCATT TTGTGTTGGA CAATCCTGAG GTGCCCAGGC AAGGCTGTAA
 1021 ATCCTGCCAG TACCACCGGG ATAAGACCGG AGACACGAAC GCCTCCTGTG CTCTGTGTTA
 1081 CATGAAAAAG AACTTCAGCT TTATTTACAG TAAGTGGAGT GAATGTGAGA GAGGCTGAGT
 1141 GCTTAAGACA TAACTGGGTG ATGCTTCAAC AGCTGTGCTA AGTGTGGTTT ATTTGTGTTT
 1201 TAGGTCCGGT GTCAGAGGAT GGTCAATCACC CTCAGAAGAA GACCACCCGT GTCCCCCTGA
 1261 TCTGTCCAGC GAAACGCCCC TGCAAGTGCA CAGACCCACC CCAGTCAGAC CCAGTGGCGA
 1321 GAGGCGAGCA GCTGTTGAAA AAATTGAGGA CTGTGTACAT GACATGGGTG GGGATGAACC
 1381 TTTGGACCTG AGCTTGAAAC GTCCCAGGAA ACTAGGCGCA GCTGCGCTTA GTCATGTGTA
 1441 AATAAAGTTG TACAATAAAA ATTATATGTG ACGCATGCAA GGTGTGGTTT ATGACTCATG
 1501 GCGGGGCTT AGTTCTATAT AAGTGGCAAC ACCTGGGCAC TGGAGCACAG ACCTTCAGGG
 1561 AGTTCTGAT GGATGTGTGG ACTATCCTTG CAGACTTTAG CAAGACACGC CGGCTGTAG
 1621 AGGATAGTTC AGACGGGTGC TCCGGGTTCT GGAGACACTG GTTGGAAGT CCTCTATCTC
 1681 GCCTGGTGTA CACAGTTAAA AAGGATTATA ACGAGGAATT TGAAAATCTT TTTGCTGATT
 1741 GCTCTGGCCT GCTAGATTCT CTGAATCTCG GCCACCAGTC CCTTTCCAG GAAAGGGTAC
 1801 TCCACAGCCT TGATTTTTC AGCCCAGGGC GCACTACAGC CGGGGTTGCT TTTGTGGTTT
 1861 TTCTGGTTGA CAAATGGAGC CAGAACACCC AACTGAGCAG GGGCTACATT CTGGACTTCG
 1921 CAGCCATGCA CCTGTGGAGG GCATGGGTCA GGCAGCGGGG ACAGAGAATC TTGAACTACT
 1981 GGCTTCTACA GCCAGCAGCT CCGGGTCTTC TTCGTCTACA CAGACAAACA TCCATGTTGG
 2041 AGGAAGAAAT GAGGCAGGCC ATGGACGAGA ACCCGAGGAG CGGTCTGGAC CCTCCGTCGG
 2101 AAGAGGAGTT GGATTGAATC AGGTATCCAG CCTGTACCCA GAGCTTAGCA AGGTGCTGAC
 2161 ATCCATGGCC AGGGGAGTGA AGAGGGAGAG GAGCGATGGG GGCAATACCG GGATGATGAC
 2221 CGAGCTGACG GCCAGTCTGA TGAATCGCAA GCGCCCAGAG CGCCTTACCT GGTACGAGCT
 2281 ACAGCAGGAG TGCAGGGATG AGTTGGGCCT GATGCAGGAT AAATATGGCC TGGAGCAGAT
 2341 AAAAACCAT TGGTTGAACC CAGATGAGGA TTGGGAGGAG GCTATTAAGA AGTATGCCAA
 2401 GATAGCCCTG CGCCAGATT GCAAGTACAT AGTGACCAAG ACCGTGAATA TCAGACATGC
 2461 TGCTACATCT CGGGGAACGG GGCAGAGGTG GTCATTGATA CCCTGGACAA GGCCGCCTTT
 2521 AGGTGTTGCA TGATGGGAAT GAGAGCCGGA GTGATGAATA TGAATTCAT GATCTTTATG
 2581 AACATGAAGT TCAATGGAGA GAAGTTTAAAT GGGGTGCTGT TCATGGCCAA CAGCCACATG
 2641 ACCCTGCATG GCTGCCACTT TTTCCGGCTTT AACAATATGT GCGCAGAGGT CTGGGGCGCT
 2701 TCCAAGATCA GGGGATGTAA GTTTTATGGC TGCTGGATGG GCGTGGTCGG AAGACCCAAG
 2761 AGCGAGATGT CTGTGAAGCA GTGTGTGTTT GAGAAATGCT ACCTGGGAGT CTCTACCGAG
 2821 GGCAATGCTA GAGTGAGGCA CTGCTCTTCC CTGGAGACGG GCTGCTTCTG CCTGGTGAAG
 2881 GGCACAGCCT CTCTGAAGCA TAATATGGTG AAGGGCTGCA CGGATGAGCG CATGTACAAC
 2941 ATGCTGACTG CCACTCGGGG GTCTGTCATA TCCTGAAGAA CATCCATGTG ACCTCCACC
 3001 CCAGAAAGAA GTGGCCAGTG TTTGAGAATA ACATGCTGAT CAAGTGCCAC ATGCACCTGG
 3061 GCGCCAGAAG GGGCACCTTC CAGCCGTACC AGTGCAACTT TAGCCAGACC AAGCTGCTGT
 3121 TGGAGAACGA TGCCCTTCTCC AGGGTGAACC TGAACGGCAT CTTTGACATG GATGTCTCGG
 3181 TGTACAAGAT CCTGAGATAC GATGAGACCA AGTCCAGGGT GCGCGCTTGC GAGTGCGGGG
 3241 GCAGACACAC CAGGATGCAG CCAGTGGCCC TGGATGTGAC CGAGGAGCTG AGACCAGACC
 3301 ACCGTGTGAT GGCCTGTACC GGGACCGAGT TCAGCTCCAG TGGGGAGGAC ACAGATTAGA
 3361 GGTAGGTTG AGTAGTGGC GTGGCTAAGG TGACTATAAA GCGGGGTGTC TTACGAGGGT

3421 CTTTTTGCTT TTCTGCAGAC ATCATGAACG GGACCGGCGG GGCCTTCGAA GGGGGGCTTT
 3481 TTAGCCCTTA TTTGACAACC CGCCTGCCAG GATGGGCGG AGTTCGTCAG AATGTGATGG
 3541 GATCGACGGT GGACGGGCGC CCAGTGCTTC CAGCAAATTC CTCGACCATG ACCTACGCGA
 3601 CCGTGGGGAA CTCGTCGCTT GACAGCACCG CCGCAGCCGC GGCAGCCGCA GCCGCCATGA
 3661 CAGCGACGAG ACTGGCCTCG AGCTACATGC CCAGCAGCAG CAGTAGCCCC TCTGTGCCCA
 3721 GTTCCATCAT CGCCGAGGAG AACTGCTGGC CCTGCTGGCC GAGCTGGAAG CCCTGAGCCG
 3781 CCAGCTGGCC GCCCTGACCC AGCAGGTGTC CGAGCTCCGC GAACAGCAGC AGCAAAATAA
 3841 ATGATTCAAT AAACACATAT TCTGATTCAA ACAGCAAAGC ATCTTTATTA TTTATTTTTT
 3901 CGCGCGCGGT AGGCCCTGGT CCACCTCTCC CGATCATTTGA GAGTGCGGTG GATTTTTTCC
 3961 AAGACCCGGT AGAGGTGGGA TTGGATGTTG AGGTACATGG GCATGAGCCC GTCCCGGGG
 4021 TGGAGGTAGC ACCACTGCAT GGCCTCGTGC TCTGGGGTCG TGTTGTAGAT GATCCAGTCA
 4081 TAGCAGGGGC GCTGGGCGTG GTGCTGGATG ATGTCCTTGA GGAGGAGACT GATGGCCACG
 4141 GGGAGCCCTT TGGTGTAGGT GTTGGCAAAG CGGTTGAGCT GGGAGGGATG CATGCCGGGG
 4201 GAGATGATGT GCAGTTTGGC CTGGATCTTG AGGTTGGCGA TGTTGCCACC CAGATCCCGC
 4261 CGGGGGTTCA TGTTGTGCAG GACCACCAGG ACGGTGTAGC CCGTGACTT GGGGAACCTA
 4321 TCATGCAACT TGGAAGGGAA TCGTGGAAG AATTTGGAGA CGCCCTTGTG CCCGCCCAGG
 4381 TTTTCCATGC ACTCATCCAT GATGATGGCG ATGGGCCCCG GGGCTGCGGC TTTGGCAAAG
 4441 ACGTTTCTGG GGTGAGAGAC ATCATAATTA TGCTCCTGGG TGAGATCATC ATAAGACATT
 4501 TTAATGAATT TTGGGCGGAG GGTGCCAGAT TGGGGGACGA TGGTTTCCCT CGGGCCCCGG
 4561 GGCGAAGTTC CCCTCGCAGA TCTGCATCTC CCAGGCTTTC ATCTCGGAGG GGGGGATCAT
 4621 GTCCACCTGC GGGGCGATGA AAAAAACGGT TTCCGGGGCG GGGGTGATGA GCTGCGAGGA
 4681 GAGCAGGTTT CTCAACAGCT GGGACTTGCC GCACCCGGTC GGGCCGTAGA TGACCCCGAT
 4741 GACGGGTGTC AGGTGGTAGT TCAAGGACAT GCAGCTGCCG TCGTCCCGGA GGAGGGGGGC
 4801 CACCTCGTTG AGCATGTCTC TAACTTGGAG GTTTTCCCGG ACGAGCTCGC CGAGGAGGCG
 4861 GTCCCGGCC AGCGAGAGGA GCTCTTGCAG GGAAGCAAAG TTTTTCAGGG GCTTGAGTCC
 4921 GTCGGCCATG GGCATCTTGG CGAGGCTCTG CGAGAGGAGT TCGAGACGTC CCAGAGCTCG
 4981 GTGACGTGCT CTACGGCATC TCGATCCAGC AGACTTCCTC GTTTCGGGGG TTGGGACGAC
 5041 TGCGACTGTA GGGCAGGAGA CGATGGCGT CCAGCGCGGC CAGCGTCATG TCCTTCCAGG
 5101 GTCTCAGGGT CCGCGTGAGG GTGGTCTCCG TCACGGTGAA GGGGTGGGCC CCTGGCTGGG
 5161 CGCTTGCAAG GGTGCGCTTG AGACTCATCC TGCTGGTGCT GAAACGGGCA CGGTCTTCGC
 5221 CCTGCGCGTC GGCAGAGTAG CAGTTGACCA TGAGCTCGTA GTTGAGGGCC TCGGCGCGCT
 5281 GGCCTTGGC GCGGAGCTTG CCCTTGGAAG AGCGTCCGCA GGCGGGACAG AGGAGGGATT
 5341 GCAGGGCGTA GAGCTTGGGC GCAAGAAAGA CCGACTCGGG AGCAAAAGCG TCCGCTCCGC
 5401 AGTGGGCGCA GACGCTCTCG CACTCGACGA GCCAGGTGAG CTCGGGCTGC TCGGGGTCAA
 5461 AAACCAGTTT TCCCCGTTT TTTTGTATGC GCTTCTTACC TCGCGTCTCC ATGAGTCTGT
 5521 GTCCGCGCTC GGTGACAAAC AGGCTGTGCG TGTCCTCGTA GACGGACTTG ATTGGCCTGT
 5581 CCTGCAGGGG CGTCCCGCGG TCCTCCTCGT AGAGAAACTC GGACCACTCT GAGACAAAGG
 5641 CGCGCGTCCA CGCCAAGACA AAGGAGGCCA CGTGCGAGGG GTAGCGGTCT TTGTCCACCA
 5701 GGGGGTCCAC CTTTTCACC GTGTGCAGAC ACATGTCCCC TTCCTCCGCA TCCAAGAAGG
 5761 TGATTGGCTT GTAGGTGTAG GCCACGTGAC CAGGGGTCCC CGACGGGGGG GTATAAAAGG
 5821 GGGCGGGTCT GTGCTCGTCC TCACTCTCTT CCGCTCGCT GTCCACGAGC GCCAGCTGTT
 5881 GGGGTAGGTA TTCCCTCTCG AGAGCGGGCA TGACCTCGGC ACTCAGGTTG TCAGTTTCTA
 5941 GAAACGAGGA GGATTTGATG TTGGCTTGCC CTGCCGCAAT GCTTTTATAG AGACTTTCAT
 6001 CCATCTGGTC AGAAAAGACT ATTTTTTAT TGTCAGGCTT GGTGGCAAAG GAGCCATAGA
 6061 GGGCGTTGGA GAGAAGCTTG GCGATGGATC TCATGGTCTG ATTTTGTGCA CGGTCCGGCG
 6121 GCTCCTTGGC CGCGATGTTG AGCTGGACAT ATTCCGCGGC GACACACTTC CATTCCGGAA
 6181 AGACGGTGGT GCGCTCGTCC GGCACGATCC TGACGCGCCA GCCGCGGTTA TGCAGGGTGA
 6241 CCAGGTCCAC GCTGGTGGCC ACCTCGCCGC GCAGGGGCTC GTTAGTCCAG CAGAGTCTGC
 6301 CGCCCTTGGC CGAGCAGAAC GGGGGCAGCA CATCAAGCAG ATGCTCGTCA GGGGGGTCCG
 6361 CATCGATGGT GAAGATGCCG GGACAGAGTT TCTTGTCAAA ATAGTCTATT TTTGAGGATG
 6421 CATCATCCAA GGCCATCTGC CACTCGCGGG CGGCCATTGC TCGCTCGTAG GGGTTGAGGG
 6481 GCGGACCCCA CGGCATGGGA TCGGTGAGGG CGGAGGCGTA CATGCCGCAA ATGTCGTAAA
 6541 CATAGATGGG CTCCGAGAAG ATGCCGATGT TGGTGGGATA ACAGCGCCCC CCGCGGATGC
 6601 TGGCGCGCAC GTATTCATAC AACTCGTGCG AGGGGCCAAG AAGGCCGGGG CCGAAATTGG
 6661 TGCGCTGGGG CTGCTCGGCG CGGAAAACAA TCTGGCGAAA GATGGCGTGC GAGTTGAGGG
 6721 AGATGGTGGG CCGTTGGAAG ATGTTAAAGT GGGCGTGGGG CAAGCGGACC GAGTCGCGGA
 6781 TGAAGTGCGC GTAGGAGTCT TGCAGCTTGG CGACGAACTC GGCCTGACG AGAACGTCCA

6841 TGGCGCAGTA GTCCAGCGTT TCGCGGATGA TGTCTAACC CGCCTCTCCT TTCTTCTCCC
 6901 ACAGCTCGCG GTTGAGGGCG TATTCCTCGT CATCCTTCCA GACTCCCGG AGCGGGAATC
 6961 CTCGATCGTC CGCACGGTAA GAGCCCAGCA TGTAGAAATG GTTCACGGCC TTGTAGGGAC
 7021 AGCAGCCCTT CTCCACGGGG AGGGCGTAAG CTTGTGCGGC CTTGCGGAGC GAGGTGTGCG
 7081 TCAGGGCGAA GGTGTCCCTG ACCATGACTT TCAAGAACTG GACTTGAAA TCCGAGTCGT
 7141 CGCAGCCGCC GTGCTCCCAT AGCTCGAAAT CCGTGCGCTT CTTGAGAGG GGGTTAGGCA
 7201 GAGCGAAAGT GACGTCATTG AAGAGAATCT TGCCTGCTCG CGGCATGAAA TTGCGGGTGA
 7261 TGCGGAAAGG GCCCGGGACG GAGGCTCGGT TGTGATGAC CTGGGCGGCG AGGACGATCT
 7321 CGTCGAAGCC GTTGATGTTG TGCCCGACGA TGTAGAGTTC CATGAATCGC GGGCGGCCTT
 7381 TGATGTGCGG CAGCTTTTGT AGCTCCTCGT AGGTGAGGTC CTCGGGGCAT TGCAGGCCGT
 7441 GCTGCTCGAG CGCCCATTC TGGAGATGTG GGTGCGCTTG CATGAAGGAA GCCCAGAGCT
 7501 CGCGGGCCAT GAGGGTCTGG AGCTCGTCGC GAAAGAGGCG GAACTGCTGG CCCACGGCCA
 7561 TCTTTTCGGG TGTGACGCAG TAGAAGGTGA GGGGGTCCCG CTCACAGCGA TCCCAGCGTA
 7621 AGCGCGCGGC TAGATCGCGA GCAAGGGCGA CCAGCTCTGG GTCCCCCGAG AATTTTCATGA
 7681 CCAGCATGAA GGGGACGAGC TGCTTGCCGA AGGACCCCAT CCAGGTGTAG GTTTCTACAT
 7741 CGTAGGTGAC AAAGAGCCGC TCCGTGCGAG GATGAGAGCC GATTGGGAAG AACTGGATTT
 7801 CCTGCCACCA GTTGGACGAG TGGCTGTTGA TGTGATGAAA GTAGAAATCC CGCCGGCGAA
 7861 CCGAGCACTC GTGCTGATGC TTGTAAGAGC GTCCGCAGTA CTCGACGCGC TGCACGGGCT
 7921 GTACCTCATC CACGAGATAC ACAGCGCGTC CCTTGAGGAG GAACTTCAGG AGTGGCGGCC
 7981 CTGGCTGGTG GTTTTCATGT TCGCTCGCTC GGGACTCACC CTGGGGCTCC TCGAGGACGG
 8041 AGAGGCTGAC GAGCCCCGCG GGGAGCCAGG TCCAGATCTC GCGCGGCGCG GGGCGGAGAG
 8101 CGAAGACGAG GCGCGCAGT TGGGAGCTGT CCATGGTGTG CCGGAGATCC AGGTCCGGGG
 8161 GCAGGGTTCT GAGGTGACC TCGTAGAGGC GGGTGAGGGC GTGCTTGAGA TGCAGATGGT
 8221 ACTTGATTTT TACGGGTGAG TTGGTGGCCG TGTCCACGCA TTGCATGAGC CCGTAGCTGC
 8281 GCGGGGCCAC GACCGTGCCG CCGTGCGCTT TTAGAAGCGG TGTGCGGAC GCGCTCCCGG
 8341 CGGCAGCGGC GGTTCGCGCC CCGCGGGCAG GGGCGGCAGA GGCACGTCGG CGTGCGCTC
 8401 GGGCAGGTCC CCGTGTGCG CCCTGAGAGC GCTGGCGTGC GCGACGACGC GGCGGTTGAC
 8461 ATCCTGGATC TGCCGCCTCT GCGTGAAGAC CACTGGCCCC GTGACTTTGA ACCTGAAAGA
 8521 CAGTTCAACA GAATCAATCT CGGCGTCATT GACGGCGGGC TGACGCAGGA TCTCTTGAC
 8581 GTCGCCCCAG TTGTCTGGT AGGCGATCTC GGACATGAAC TGCTCGATCT CCTCTCTCTG
 8641 GAGATCGCCG CGACCCGCGC GCTCCACGGT GCGCGGAGG TCATTGAGA TGCAGCCCAT
 8701 GAGCTGCGAG AAGGCCCCCA GGGCGCTCTC GTTCCAGACG CCGCTGTAGA CCACGTCCTC
 8761 GTCGGCGTCG CGCGCGCGCA TGACCACCTG CCGGAGGTTG AGCTCCACGT GCCGCGCGAA
 8821 GACGGCGTAG TTGCGCAGGC GCTGGAAGAG GTAGTTGAGG GTGGTGCGCA TGTGCTCGGT
 8881 GACGAAGAAG TACATGATCC AGCGGCGCAG GGGCATCTCG CTGATGTGCG CGATGGCCTC
 8941 CAGCCTTTCC ATGGCTCGT AGAAATCCAC GCGGAAGTTG AAAAAGTGG CGTTGCGGGC
 9001 CGAGACCGTG AGCTCGTCTT CCAGGAGCCT GATGAGCTCG GCGATGGTGG CCGCACCTC
 9061 GCGCTCGAAA TCCCCGGGGG CCTCGTCTCT TTCTCTTCT TCCATGACAA CCTCTTCTAT
 9121 TTCTTCTCTT GGGGGCGGTG GTGGTGCGCG GGGCCGACGA CGACGGCGAC GCACCGGGAG
 9181 ACGGTCGACG AAGCGCTCGA TCATCTCCCC GCGGCGGCGA CGCATGGTTT CCGTGACGGC
 9241 GCGACCCCGT TCGCGAGGAC GCAGCGTGAA GACGCCGCGG GTCATCTCCC GGTATGGGG
 9301 CCGGTCCCCG TTGGGCAGCG AGAGGGCGCT GACGATGCAT CTTATCAATT GCGGTGTAGG
 9361 GGACGTGAGC GCGTCGAGAT CGACCGGATC GGAGAATCTT TCGAGGAAAG CGTCTAGCCA
 9421 ATCGCAGTCG CAAGGTAAGC TCAAACACGT AGCAGCCCTG TGGACGCTGT TAGAATTGCG
 9481 GTTGCTAATG ATGTAATTGA AGTAGGCGTT TTTGAGGCGG CGGATGGTGG CGAGGAGGAC
 9541 CAGGTCTTTG GGTCCCGCTT GCTGGATGCG GAGCCGCTCG GCCATGCCCC AGGCTTGGCC
 9601 CTGACACCGG CTTAGGTTCT TGTAGTAGTC ATGCATGAGC CTCTCGATGT CATCACTGGC
 9661 GGAGGCGGAG TCTTCCATGC GGGTGACCCC GACGCCCTG AGCGGCTGCA CGAGCGCCAG
 9721 GTCGGCGACG ACGCGCTCGG CGAGGATGGC CTGTTGCACG CCGGTGAGGG TGTCTTGAA
 9781 GTCGTCCATG TCGACGAAGC GGTGGTAGGC CCTGTGTTG ATGGTGTAAG TGCAGTTGGC
 9841 CATGAGCGAC CAGTTGACGG TCTGCAGGCC GGGTGACAG ACCTCGGAGT ACCTGAGCCG
 9901 CGAGAAGGCG CGCGAGTCGA AGACGTAGTC GTTGCAAGTG CGCACAAGGT ACTGGTATCC
 9961 GACTAGGAAG TGCGGCGGCG CTGGCGGTA GAGCGGCCAG CGCTGGGTGG CCGGCGCGCC
 10021 CGGGGCCAGG TCCTCGAGCA TGAGGCGGTG GTAGCCGTAG AGGTAGCGGG ACATCTAGGT
 10081 GATGCCGGCA GCGGTGGTGG AGGCGCGCGG GAACTCGCGG ACGCGGTTCC AGATGTTGCG
 10141 CAGCGGCAGG AAATAGTCCA TGGTGGCAC GGTCTGGCCG GTGAGACGCG CGCAGTCATT
 10201 GACGCTCTAG AGGCAAAAAC GAAAGCGGTT GAGCGGGCTC TTCTCCGTA GCCTGGCGGA

10261 ACGCAAACGG GTTAGGCCGC GCGTGTACCC CGGTTTCGAGT CCCCTCGAAT CAGGCTGGAG
10321 CCGCGACTAA CGTGGTATG GCACTCCCGT CTCGACCCGA GCCCAGTAGC CGCCAGGATA
10381 CGCGGGAAGA GCCCTTTTGT CCGGCCGARG GGAGTCGCTA GACTTGAAAG CGGCCGAAAA
10441 CCCC GCCGG TAGTGGCTCG CGCCCGTAGT CTGGAGAAGC ATCGCCAGGG TTGAGTCGCG
10501 GCAGAACCCG GTTCGCGGAC GCGCGCGGCG AGCGGGACTT GGTACCCCG CCGATTTAAA
10561 GACCCACAGC CAGCCGACTT CTCCAGTTAC GGGAGCGAGC CCCCTTTTTT CTTTTTGCCA
10621 GATGCATCCC GTCTGCGCC AAATGCGTCC CACCCCCCG GCGACCACCG CGACCGCGGC
10681 CGTAGCAGGC GCCGGCGCTA GCCAGCCACA GCCACAGACA GAGATGGACT TGGAAAGAGGG
10741 CGAAGGGCTG GCGAGACTGG GGGCGCCTTC CCCGGAGCGA CACCCCCGCG TGCAGATGCA
10801 GAAGGACGTG CGCCCGGCGT ACGTGCCTGC GCAAAACCTG TTCAGGGACC GCAGCGGGGA
10861 GGAGCCCGAG GAGATGCGCG ACTGCCGTT TCGGGCGGGC AGGGAGCTGC GCGAGGGCCT
10921 GGACCCGAG CGCGTGCTGC GCGACGAGGA TTTTCGAGCCG AACGAGCAGA CGGGGATCAG
10981 CCCC CGCGC GCGCACGTGG CCGCGGCCAA CCTGGTGACG GCCTACGAGC AGACGGTGAA
11041 GCAGGAGCGC AACTTCCAAA AGAGTTTCAA CAACCATGTG CGCACCCCTGA TCGCGCGCGA
11101 GGAGGTGGCC CTGGGCTGA TGCACCTGTG GGACCTGGCG GAGGCCATCG TGCAGAACCC
11161 GGACAGCAAG CCTCTGACGG CGCAGCTGTT CCTGGTGGTA CAGCACAGCA GGGACAACGA
11221 GCGGTTTCAGG GAGGCGCTGC TAAACATCGC CGAGCCCGAG GGTGCTGGC TGCTGGAGCT
11281 GATCAACATC TTGCAGAGCA TCGTAGTTCA GGAGCGCAGC CTGAGCTTGG CCGAGAAGGT
11341 GGCGGCAATC AACTACTCGG TGCTTAGCCT GGGCAAGTTT TACGCGCGCA AGATTTACAA
11401 GACGCCGTAC GTGCCCATAG ACAAGGAGGT GAAGATAGAC AGCTTTTACA TGCGCATGGC
11461 GCTCAAGGTG CTGACGCTGA GCGACGACCT GGGCGTGATC CGCAACGACC GCATCCACAA
11521 GGCCGTGAGC GCGAGCCGGC GCGCGAGCT GAGCGACCGC GAGCTGATGC TGAGCCTGCG
11581 CCGGGCGCTG GTAGGGGGCG CCGCCGGCGG CGAGGAGTCY TACTTCGACA TGGGGGCGGA
11641 CCTGCATTGG CAGCCGAGCC GCGCGCCTT GGAGGCCCGC TACGGTCCAG AGGACTTGGG
11701 TGAGGAAGAG GAAGAGGAGG AGGATGCACC CGCTGCGGGG TACTGACGCC TCCGTGATGT
11761 GTTTTATAGT GCAGCAAGCC CCGGACCCCG CCATAAGGGC GCGCGTGCAA AGCCAGCCGT
11821 CCGGTCTAGC ATCGGACGAC TGGGAGGCTG CGATGCAACG CATCATGGCC CTGACGACCC
11881 GCAACCCCGA GTCCTTTAGA CAACAGCCGC AGGCCAACAG ACTCTCGGCC ATTCTGGAGG
11941 CGGTGGTCCC TTCTCGGACC AACCACACG ACGAGAAGGT GCTGGCGATC GTGAACGCGC
12001 TGGCGGAGAA CAAGGCCATC GTCCCGACG AGGCCGGGCT AGTGTAACA GCCCTGCTGG
12061 AGCGCGTAGG CCGCTACAAC AGCACAACG TGCAGTCCAA CCTGGACCGG CTGGTGACGG
12121 ACGTGCGCGA AGCCGTGGCG CAGCGCGAGC GGTTCAGAA CGAGGGCCTG GGCTCGCTGG
12181 TGGCGCTGAA CGCCTTCCTG GCGACGAGC CGGCGAACGT GCCGCGCGGG CAGGATGATT
12241 ACACCAACTT TATCAGCGCG CTGCGGCTGA TGGTGACCGA GGTGCCCCAG AGCGAGGTGT
12301 ACCAGTCGGG CCCGACTAC TTTTCCAAA CTAGCAGACA GGGCCTGCAA ACGGTGAACC
12361 TGAGCCAGGC TTTCAAGAAC CTGCGCGGGC TGTGGGGCGT GCAGGCGCCC GTGGGCGACC
12421 GGTGACGGT GAGCAGCTTG CTGACGCCCCA ACTCGCGGCT GCTGCTGCTG CTGATCGCGC
12481 CCTTACCGA CAGTGGCAGC GTAAACCGCA ACTCGTACCT GGGTCACCTG CTAACGCTGT
12541 ACCGCGAGGC CATAGGCCAG GCGCAGGTGG ACGAGCAGAC CTTCAGGAG ATCAGTAGCG
12601 TGAGCCGCGC GCTGGGGCAG AACGACACCG ACAGTCTGAG GGCCACCCTG AACTTCTTGC
12661 TGACCAATAG ACAGCAGAAG ATCCCGGCGC AGTACGCGCT GTCGGCCGAG GAGGAGCGCA
12721 TCCTGAGATA TGTGCAGCAG AGCGTAGGGC TTTTCTGAT GCAGGAGGGG GCCACTCCCA
12781 GCGCCGCGCT GGACATGACC GCGCGCAACA TGGAACTAG CATGTACGCC GCCAACCAGC
12841 CGTTTATCAA TAAGCTAATG GACTACCTGC ATCGCGCGGC GTCCATGAAC TCGGACTACT
12901 TTACCAATGC CATTTTGAAC CCGCACTGGC TTCCGCGGCC GGGGTTCCTAT ACGGGCGAGT
12961 ACGACATGCC CGACCCCAAC GACGGGTTTT TGTGGGACGA CGTGGACAGC GCGGTGTTTT
13021 CACCGACCTT GCAAAAGCGC CAGGAGGCGG TCGCACGCC CGCGAGCGAG GCGCGGTGG
13081 GTCGGAGCCC CTTTCTAGC TTAGGGAGTT TGCATAGCTT GCCGGGCTCT GTGAACAGCG
13141 GCAGGGTGAG CCGGCCGCGC TTGCTGGGCG AGGACGAGTA CCTGAACGAC TCGCTGCTGC
13201 AGCCGCCGCG GGTCAAGAAC GCCATGGCCA ATAACGGGAT AGAGAGTCTG GTGGACAAAC
13261 TGAACCGCTG GAAGACCTAC GCTCAGGACC ATAGGGAGCC TGCGCCCGCG CCGCGGCGAC
13321 AGCGCCACGA CCGGCAGCGG GGCCTGGTGT GGGACGACGA GGAATCGGCC GACGATAGCA
13381 GCGTGTGGA CTGGGCGGG AGCGGTGGG TCAACCGAT ATCGCGCATC ATCGAGCCCA
13441 AACTGGGGCG ACGGATGTTT TGAATGCAAA ATAAACTCA CCAAGGCCAT GTGCTGCTT
13501 CTCTTCTTGT TTAGAGATGA GCGGTGCGGT GGTGCTTCTC TCTCTCTCTC CTCTGCTGCA
13561 GAGCGTGATG GCGCAGGCGA CCCTGGAGGT TCCGTTTGTG CCTCCGCGGT ATATGGCTCC
13621 TACGGAGGGC AGAAACAGCA TTCGTTACTC GGAGCTGGCT CCGTTGTACG ACACCACTCG

13681 CGTGTAACCTG GTGGACAACA AGTCGCGGGA CATCGCTTCC CTGAACTATC AAAACGACCA
 13741 CAGCAACTTC CTGACCACGG TGGTGCAGAA CAACGATTTC ACCCCCGCCG AGGCTAGCAC
 13801 GCAGACGATA AATTTTGACG AGCGGTGCGG GTGGGGCGGT GATCTGAAGA CCATTCTGCA
 13861 CACCAACATG CCCAATGTGA ACGAGTACAT GTTCACCAGC AAGTTTAAGG CGCGGGTGAT
 13921 GGTGGCTAGA AACACCCAC AGGGGGTAGA AGCAACAGAT TTAAGCAAGG ATATCTTAGA
 13981 GTATGAGTGG TTTGAGTTTA CCCTGCCCCG GGGCAACTTT TCCGAGACCA TGACCATAGA
 14041 CCTGATGAAC AACGCCATCT TGGAAAACCTA CTTGCAAGTG GGGCGGCAAA ATGGCGTGCT
 14101 GGAGAGCGAT ATTGGAGTCA AGTTTGACAG CAGAAATTTT AAGCTGGGCT GGGACCTGT
 14161 GACCAAGCTG GTGATGCCAG GGGTCTACAC CTACGAGGCC TTTCACCCGG ACGTGGTGCT
 14221 GCTGCCGGGC TCGGGGGTGG ACTTCACAGA GAGCCGCTG AGCAACCTCC TGGGCATTCCG
 14281 CAAGAAGCAA CCTTTCCAAG AGGGCTTCAG AATCATGTAT GAGGATCTAG AAGGGGGCAA
 14341 CATCCCCGCC CTGCTGGATG TGCCCAAGTA CTTGGAAGC AAGAAGAAGT TAGAGGAGGC
 14401 ATTGGAGAAT GCTGCTAAAG CTAATGGTCC TGCAAGAGGA GACAGTAGCG TCTCAAGAGA
 14461 GGTGAAAAG GCAGCTGAAA AAGAACTTGT TATTGAGCCC ATCAAGCAAG ATGATACCAA
 14521 GAGAAGTTAC AACCTCATCG AGGGAACCAT GGACACGCTG TACCGCAGCT GGTACCTGTC
 14581 CTATACCTAC CGGGACCCTG AGAACGGGGT GCAGTCGTGG ACGCTGCTCA CCACCCCGGA
 14641 CGTCACCTGC GCGCGGAGC AAGTCTACTG GTCGCTGCCG GACCTCATGC AAGACCCCGT
 14701 CACCTTCCGT TCTACCCAGC AAGTCAGCAA CTACCCCGTG GTCGGCGCCG AGCTCATGCC
 14761 CTTCCGCGCC AAGAGCTTTT ACAACGACCT CGCCGTCTAC TCCAGCTCA TCCGCAGCTA
 14821 CACCTCCCTC ACCCACGTCT TCAACCGCTT CCCCAGAAC CAGATCCTCT GCCGTCCGCC
 14881 CGCGCCACC ATCACCACCG TCAGTAAAAA CGTGCCTGCT CTCACAGATC ACGGGACGCT
 14941 ACCGCTGCGC AGCAGTATCC GCGGAGTCCA GCGAGTGACC GTCAGTACG CCCGTCGCCG
 15001 CACCTGTCCC TACGTCTACA AGGCCCTGGG CATAGTCGCG CCGCGTGTGC TTTCCAGTCG
 15061 CACCTTCTAA AAAATGTCTA TTCTCATCTC GCCCAGCAAT AACACCGGT GGGGTATTAC
 15121 TAGGCCCAGC AGCATGTACG GAGGAGCCAA GAAACGTCCC AGCAGCACC CGTCCGCGTC
 15181 CGCGGCCACT TCCGCGCTCC GTGGGGCGCT TACAAGCGCG GCGGACTGC CACCGCCGCC
 15241 GCCGTGCGCA CCACCGTCGA CGACGTCATC GACTCGGTGG TCGCCGACGC GCGCAACTAT
 15301 ACTCCCGCCC CTTCGACCGT GGACGCGGTT CATTGACAGC GTGGTGGCGA CGCGCGGGCG
 15361 ATATGCCAGA CGCAAGAGCC GCGGGGCGGA CGGATCGCCC AGGCGCCATT CGGAGCACGC
 15421 CCGCCATGGG CCGCGCGCCG AGCTCTGTG CGCCGCGCCA GACGCACGGG CCGCCGGGCC
 15481 ATGATGCGAG CCGCGCGCCG CGCCGCCACT GCACCCCCCG CAGGCAGGAC TCGCAGACGA
 15541 GCGCGCGCCG CCGCGCGCCG GGCCATCTCT AGCATGACCA GACCCAGGCG CGGAAACGTG
 15601 TACTGGGTGC GCGACTCCGT CACGGGCGTG CGCGTGCCCG TCGCACCCCG TCCTCCTCGT
 15661 CCCTGATCTA ATGCTTGTGT CCTCCCCCGC AAGCGACGAT GTCAAAGCGC ATCTACAAGA
 15721 GAGATGCTCC AGGTGCTCGC CCCGAGATT TACGGACCAC CCCAGGCGGA CCAGAAACCC
 15781 CGCAAAATCA AGCGGGTTAA AAAAAAGGAT GAGGTGGACG AGGGGGCAGT AGAGTTTGTG
 15841 CGCGAGTTCG CTCCGCGGGC GCGCGTAAAT TGGAAGGGGC GCAGGTGCAC GCGTGTGCG
 15901 GCGCGGACG GCGGTGGTGT TCACGCCCCG CGAGCGGTCC TCGGTCAGGA GCAAGCGTAG
 15961 CTATGACGAG GTGTACGGC ACGACGACAT CCTGGACCAG GCGGCAGAGC GGGCGGGCGA
 16021 GTTTGCCCTAC GGAAGCGGT CGCGCAAGA GGAGCTGATC TCGCTGCCG TGGACGAGAG
 16081 CAATCCCAG CCGAGCCTGA AGCCCGTGAC CTGCAGCAGG TGCTGCCCA GCGGTGCTG
 16141 CTGCCGAGCC GCGGGATCAA GCGCGAGGGC GAGAACATGT ACCCGACCAT GCAGATCATG
 16201 GTGCCCAAGC GCGGCGCGT GGAGGAAGTG CTGGACACCG TGAAAATGGA TGTGGAGCCC
 16261 GAGGTCAAGG TGCGCCCCAT CAAGCAGGTG GCGCGGGGCC TGGGCGTGCA GACCGTGGAC
 16321 ATTCAGATCC CCACCGACAT GGATGTCGAC AAAAAACCTT CGACCAGCAT CGAGGTGCAG
 16381 ACCGACCCCT GGCTCCCAGC CTCCACCGCT ACCGCTTCCA CTTCTACCGT CGCCACGGTC
 16441 ACCGAGCCTC CCAGGAGGCG AAGATGGGGC CCGCCAACC GGCTGATGCC CAACTACGTG
 16501 TTGCATCCTT CCATTATCCC GACGCCGGGC TACCGCGGCA CCGGTACTA CGCCAGCCGC
 16561 AGGCGCCAG CCAGCAAACG CCGCCGCCG ACCGCCACCC GCGCCGCTT GCCCCCCGCC
 16621 CGCGTGCGCC GCGTAACCAA CGCGCCGGG CCGCTCGCTC GTTCTGCCA CCGTGCGCTA
 16681 CCACCCAGC ATCCTTTAAT CCGTGTGCTG TGATACTGTT GCAGAGAGAT GGCTCTCACT
 16741 TGCCCGCTGC TCCGAATTAC CGAGGAAGAT CCCGCCGAG GAGAGGCATG GAGTGGCGGC
 16801 GCAGGCAGCG GCCTGAACCG CCGCGGCGG CGGGCCATGC GCAGGCGCCT GAGTGGCGGC
 16861 TTTCTGCCCG CGCTCATCCC CATAATCGCG GCGGCCATCG GCACGATCCC GGCATAGCT
 16921 TCCGTGCGC TGCAGGCGTC GCAGCGCGT TGATGTGCGA ATAAAGCCTC TTTAGACTCT
 16981 GACACACCTG GTCCTGTATA TTTTATAGA GGAAGACATC AATTTTGCCT CCCTGGCTCC
 17041 GCGGCACGGC ACGCGGCCGT TCATGGGCAC CTGGAACGAG ATCGGCACCA GCCAGCTGAA

```

17101 CGGGGGCGCC TTCAATTGGA GCAGTGTCTG GAGCGGGCTT AAAAATTTTCG GCTCGACGCT
17161 CCGGACCTAT GGGAAACAAGG CCTGGAATAG TAGCACGGGG CAGTTGTTGA GGGAAAAGCT
17221 CAAAGACCAG AACTTCCAGC AGAAGGTGGT GGACGGCCTG GCCTCGGGCA TTAACGGGGT
17281 GGTGGACATC GCGAACCAGG CAGTGCAGCG CGAGATAAAC AGCCGTCTGG ACCCGCGGCC
17341 GCCCACGGTG GTGGAGATGG AAGATGCAAC TCTTCCGCCG CCGAAGGGCG AGAAGCGGCC
17401 GCGGCCAGAT GCGGAGGAGA CGATCCTGCA GGTGGACGAG CCGCCTTCGT ACGAGGAGGC
17461 CGTGAAGGCC GGCATGCCCA CCACGCGCAT CATCGCGCCA CTGGCCACGG GTGTAATGAA
17521 ACCCGCCACC CTTGACCTGC CTCCACCACC CACGCCCGCT CCACCGAAGG CAGCTCCGGT
17581 TGTGCAGCCC CCTCCGGTGG CGACCGCGCT GCGCCGCGTC CCCGCCCGCC GCCAGCCCCA
17641 GAACTGGCAG AGCACGCTGC ACAGTATTGT GGGCCTGGGA GTGAAAAGTC TGAAGCGCCG
17701 CCGATGCTAT TGAGAGAGAG GAAGGAGGAC ACTAAAGGGA GAGCTTAACT TGTATGTGCC
17761 TTACCGCCAG AGAACGCGCG AAGATGGCCA CCCCTCGAT GATGCCGCG TGGGCGTACA
17821 TGCACATCGC CGGGCAGGAC GCCTCGGAGT ACCTGAGCCC GGGTCTGGTG CAGTTTGCCC
17881 GCGCCACCGA CACGTACTTC AGCCTGGGCA ACAAGTTTAG GAACCCACG GTGGCCCCGA
17941 CCCACGATGT GACCACGAC CGGTCCCAGC GTCTGACGCT GCGCTTTGTG CCCGTGGATC
18001 GCGAGGACAC CAGTACTCGT ACAAGGCGCG CTTCACTCTG GCCGTGGGCG ACAACCGGGT
18061 GCTAGACATG GCCAGCACGT ACTTTGACAT CCGCGGCGTC CTGGACCGCG GTCCCAGTTT
18121 CAAACCCTAC TCGGGCACGG CTTACAACAG CCTTGCCCCC AAGGGCGCTC CCAATCCAG
18181 TCAGTGGGTT GCCAAAGAAA ATGGTCAGGG AACTGATAAG ACACATACTT ATGGCTCAGC
18241 TGCCATGGGA GGAAGCAACA TCACCATTGA AGGTTTAGTA ATTGGAATG ATGAAAAAGC
18301 TGAGGATGGC AAAAAAGATA TTTTGGCAA TAAACTTTAT CAGCCAGAAC CTCAAGTAGG
18361 TGAAGAAAAC TGGCAAGAGT CTGAAGCCTT CTATGGAGGC AGAGCTCTTA AGAAAGACAC
18421 AAAAATGAAG CCCTGCTATG GCTCATTTGC AAGACCTACC AATGAAAAAG GCGGACAAGC
18481 TAAATTTAAG CCAGTGAAG AGGGGAGCA ACCTAAAGAT TATGACATAG ATTTGGCTTT
18541 CTTTGACACA CCTGGAGGCA CCATCACAGG AGGCACAGAC GAAGAATATA AAGCAGACAT
18601 TGTGTTGTAC ACTGAAAATG TCAACCTTGA ACCCCAGAC ACCCAGTGG TATACAAGCC
18661 AGGAAAAGAG GATGACAGTT CAGAAGTAAA TTTGACACAG CAGTCCATGC CCAACAGGCC
18721 TAACTACATT GGCTTCAGAG ACAACTTTGT GGGACTCATG TACTACAACA GTACTGGCAA
18781 CATGGGTGTG CTGGCTGGTC AGGCCTCTCA ATTGAATGCT GTGGTCGACT TGCAAGACAG
18841 AAACACCGAG CTGTCTTACC AGCTCTTGCT AGATTCTCTG GGTGACAGAA CCAGATACTT
18901 CAGCATGTGG AACTCTGCGG TGGATAGCTA TGATCCAGAT GTCAGGATCA TTGAAAATCA
18961 TGGTGTGGAA GATGAACTTC CAAACTATTG CTTCCCATG AATGGCACTG GCACCAATTG
19021 AACATATCTT GCGTAAAGG TGAACCAGA TCAAGATGGT GATGTTGAAA GCGAGTGGGA
19081 TAAAGATGAT ACCATTGCAA GGCAGAATCA AATCGCCAAG GGCAACGCTT TTGCCATGGA
19141 GATCAACCTC CAGGCCAACC TGTGGAAGAG TTTTCTGTAC TCGAACGTGG CCTTGTACCT
19201 GCCCGACTCC TACAAGTACA CGCCGGCCAA TGTTACGCTG CCCGCCAACA CCAACACCTA
19261 CGAGTACATG AACGGCCGCG TGGTAGCCCC CTCGCTGGTG GACGCCTACA TCAACATAGG
19321 CGCCGATGG TCGCTGGACC CCATGGACAA CGTCAACCCC TTCAACCACC ACCGCAATGC
19381 GGGCTTGC GC TACCGCTCCA TGCTTCTGGG CAACGGCCGC TACGTGCCCT TCCACATCCA
19441 AGTGCCCCAA AAGTCTTTG CCATCAAGAA CCTGCTCCTG CTCCCGGGCT CCTACACCTA
19501 CGAGTGAAC TTCCGCAAGG ATGTCAACAT GATCCTGCAG AGTTCCCTCG GCAACGACCT
19561 GCGCGTCGAC GGCGCTCCG TCCGCTTCGA CAGCGTCAAC CTCTACGCCA CCTTCTTCCC
19621 CATGGCGCAC AACACCGCCT CCACCTGGA AGCCATGCTG CGCAACGACA CCAACGACCA
19681 GTCTTCAAC GACTACCTCT CGGCCGCCAA CATGCTCTAC CCCATCCCGG CCAAGGCCAC
19741 CAACGTGCCC ATCTCCATCC CCTCGCGCAA CTGGGCGGCT TTTGCGGGCT GGAGTTTCAC
19801 CCGTCTGAAA ACCAAGGAAA CTCCCTCCCT CGGCTCGGGT TTTGACCCCT ACTTTGTCTA
19861 CTCGGGCTCG ATCCCTTACC TTGACGGACC CTTTACCTT AACCACACCT TCAAGAAAGT
19921 CTCCATCATG TTCGACTCCT CGGTGAGCTG GCGCGGCAAC GACCGGCTGC TCACGCCGAA
19981 CGAGTTCGAG ATCAAGCGCA GCGTCGACGG GGAAGGCTAC AACGTGGCCC AATGCAACAT
20041 GACCAAGGAC TGGTTCCTCG TCCAGATGCT CTCCCCTAC AACATCGGCT ACCAGGGCTT
20101 CCACGTGCCC GAGGGCTACA AGGACCGCAT GTACTCCTTC TTCCGCAACT TCCAGCCCAT
20161 GAGCAGGAG GTGGTCGATG AGATCAACTA CAAGGACTAC AAGGCCGTCA CCCTGCCCTT
20221 CCAGCACAAC AACTCGGGCT TCACCGGCTA CCTTGCACCC ACCATGCGCC AAGGGCAGCC
20281 CTACCCCGCC AACTTCCCTT ACCCGCTCAT CGGCCAGACA GCGGTGCCAT CCGTCACCCA
20341 GAAAAAGTCTC CTCTGCGACA GGGTCATGTG GCGCATCCCC TTCTCCAGCA ACTTCATGTC
20401 CATGGGCGCC TTCACCGACC TGGGTGAGAA CATGTTCTAC GCCAACTCGG CCCACGCGCT
20461 CGACATGACC TTCGAGGTGG ACCCATGGA TGAGCCACCC GTCTCTATC TTCTCTTCCA

```

- 34 -

20521 AGTGTTCGAC GTGGTCAGAG TGCACCAGCC GCACCGCGGC GTCATCGAGG CCGTCTACCT
20581 GCGCACGCCG TTCTCCGCCG GAAACGCCAC CACCTAAGCA TGAGCGGCTC CAGCGAAAGA
20641 GAGCTCGCGT CCATCGTGCG CGACCTGGGC TGCGGGCCTA CTTTTTGGGC ACCCACGACA
20701 CAGCGATTCC CGGGCTTTCT TGCCGGCGAC AAGCTGGCCT GCGCCATTGT CAACACGGCC
20761 GGCCGCGAGA CCGGAGGCGT GCACTGGCTC GCCTTCGGCT GGAACCCGCG CTCGCGCACC
20821 TGCTACATGT TCGACCCCTT TGGGTCTCTG GACCGCCGCG TCAAGCAGAT TTACAGCTTC
20881 GAGTACGAGG CCATGCTGCG CCGAAGCGCC GTGGCCTCTT CGCCCGACCG CTGTCTCAGC
20941 CTCGAACAGT CCACCCAGAC CGTGCAAGGG CCCGACTCCG CCGCCTGCGG ACTTTTCTGT
21001 TGCATGTTCT TGCATGCCTT CGTGCACTGG CCCGACCGAC CCATGGACGG GAACCCACC
21061 ATGAAGTTGC TGACGGGGT GCCAACCGG ATGCTACAAT CGCCACAGGT GCTGCCACC
21121 CTCAGGCGCA ACCAGGAGGA GCTCTATCGC TTCTTCGCGC GCCACTCCCC TTACTTTTCG
21181 TCCCAACGCG CCGCCATCGA ACACGCCACC GCTTTTGACA AAATGAAACA TACTGCTGTA
21241 TCTCAATAAA CAGCACTTTT ATTTTACATG CACTGGAGTA TATGCAAGTT ATTTAAAGT
21301 CGAAGGGGTT CTCGCGCTCA TCGTTGTGCG CCGCGCTGGG GAGGGCCACG TTGCGGTACT
21361 GGTACTTGGG CTGCCACTTG AACTCGGGGA TCACCAGTTT GGGCACTGGG GTCTCGGGGA
21421 AGGTCTCGCT CCACATACGC CGGCTCATCT GCAGGGCGCC CAGCATGTCC GGGGCGGATA
21481 TCTTGAAATC GCAGTTGGGA CCGGTGCTCT GCGCGCGCGA GTTGCGGTAC ACGGGGTTGC
21541 AGCACTGGAA CACCATCAGA CTGGGGTACT TTACGCTGGC CAGCACGCTC TTGTCTGCTGA
21601 TCTGATCCTT GTCCAGATCC TCGGCGTTGC TCACGCCGAA TGGGGTCATC TTGCACAGTT
21661 GGCGACCCAG GAATGGCACG CTCGTAGGCT TGTGGTTACA CTCGCAGTGC ACGGGCATCA
21721 GCATCATCCC CGCGCCGCGC TGCATATTCG GGTAGAGGCC TTGACAAAGG CCGTGATCTG
21781 CTTGAAAGCT TGTGGGCCT TGGCCCCCTC GCTGAAAAAC AGGCCGACG TCTTCCCGCT
21841 GAACTGGTTA TTCCCGCACC CGGCATCCTG CACGCAGCAG CGCGCGTCAT GGCTGGTCAG
21901 TTGCAACCAG CTTCTTCCCC AGCGGTTCTG GGTCACTTG GCTTTGCTGG GTTGCTCCTT
21961 CAACGCGCGC TGCCCGTTCT CGTGGTCAC ATCCATCTCC ACCACGTGGT CCTTGTGGAT
22021 CATCACCGTT CCATGCAGAC ACTTGAGCTG GCCTTCCACC TCGGTGCAGC CGTGATCCCA
22081 CAGGGCACTG CCGGTGCACT CCCAGTTCTT GTGCGCGATC CCGCTGTGGC TGAAGATGTA
22141 ACCTTGCAAG AGGCGACCCA TGATGGTGCT AAAGCTCTTC TGGGTGGTGA AGGTTAGTTG
22201 CAGACCGCGG GCCTCCTCGT TCATCCAGGT CTGGCACATC TTTTGAAGA TCTCGGTCTG
22261 CTCGGGCATG AGCTTGTAAG CATCGCGCAG GCCGCTGTCTG ACGCGGTAAC GTTCCATCAG
22321 CACGTTTCATG GTATCCATGC CCTTTTCCCA GGACGAGACC AGAGGCAGAC TCAGGGGGTT
22381 GCGCACGTTT AGGACACCGG GGGTCKCGGG CTCGACGATA CGTTTTCCGT CCTTGCCCTT
22441 CTTCAACAGA ACCGGAGGCT GGCTGAATCC CACTCCCACA ATCACGGCAT CTTCTTGGGG
22501 CATCTCTTCG TCGGGGTCTA CCTTGCTCAC ATGCTTGGTC TTTCTGGCTT GCTTCTTTTT
22561 TGGAGGGCTG TCCACGGGGA CCACGTCTCTC TCGGAAGACC CGGAGCCAC CGCTGTGATAC
22621 TTTCGGCGCT TGGTGGGCAG AGGAGGTGGC GGCGGCGAGG GGCTCCTCTC GTGCTCCGGC
22681 GGATAGCGCG CCGACCCGTG GCCCGGGGGC GGAGTGGCCT CTCGCTCCAT GAACCGGCGC
22741 ACGTCTGACT GCCGCCGGCC ATTGTTTCTT AGGGGAAGAT GGAGGAGCAG CCGCGTAAGC
22801 AGGAGCAGGA GGAGGACTTA ACCACCCACG AGCAACCCAA AATCGAGCAG GACCTGGGCT
22861 TCGAAGAGCC GGCTCGTCTA GAACCCACA GGATGAACAG GAGCACGAGC AAGACGCAGG
22921 CCAGGAGGAG ACCGACGCTG GGCTCGAGCA TGGCTACCTG GGAGGAGAGG AGGATGTGCT
22981 GCTGAAACAC CTGCAGCGCC AGTCCCTCAT CCTCCGGGAC GCCCTGGCCG ACCCGAGCGA
23041 AACCCCCCTC AGCGTCGAGG AGCTGTGTCTG GGCTACGAG CTCAACCTCT TCTCGCCGCG
23101 CGTGCCCCC AAACGCCAGC CCAACGGCAC CTGCGAGCCC AACCCGCGTC TCAACTTCTA
23161 TCCCGTCTTT GCGGTCCCCG AGGCCCTTGC CACCTATCAC ATCTTTTCA AGAACCAAAA
23221 GATCCCCGTC TCCTGCCGCG CCAACCGCAC CCGCGCCGAC GCGCTCCTCG CTCTGGGGCC
23281 CGGCGCGCGC ATACCTGATA TTGCTTCCCT GGAAGAGTGC CCAAAATCTT CGAAGGGGCTC
23341 GGTGCGGACG AGACGCGCGC GGCGAAACGC TCTGAAAGAA ACAGCAGAGG AAGAGGGTCA
23401 CACTAGCGCC CTGGTAGAGT TGGAAAGCGA CAACGCCAGG CTGGCCGTGC TCAAGCGCAG
23461 CGTTGAGCTC ACCCACTTCC CCTACCCCGC CGTCAACCTC CCGCCCAAGG TCATGCGTCTG
23521 CATCATGGAT CAGCTAATCA TGCCCCACAT CGAGGCCCTC GATGAAAGTC AGGAGCAGCG
23581 CCCCAGGAGC ACCCGGCCCC TGGTCAGCGA TGAGCAGCTT GCGCGCTGGC TTGGTACCCG
23641 CGACCCCCAG GCCCTGGAGC AGCGGCGCAA GCTCATGCTG GCCGTGGTCC TGGTCACCCCT
23701 CGAGCTCGAA TGCAATGCGAC GCTTTTTCAG CGACCCCGAG ACCTGCGCAA GGTGCGAGGAG
23761 ACCTGCACTA CACTTTTAGC ACGTTTCGTC AGGCAGGCAT GCAAGATCTC CAACGTGGAG
23821 CTGACCAACT GGTCTCCTGC CTGGGAATCC TGCACGAGAA CCGCCTGGGG CAGACAGTGC
23881 TCCACTCGAC CCTGAAGGGC GAGGCGCGGC GGGACTATGT CCGCGACTGC GTCTTTCTCT

23941 TTCTCTGCCA CACATGGCAA GCTGCCATGG GCGTGTGGCA GCAGTGTCTC GAGGACGAGA
24001 ACCTGAAGGA GCTGGACAAG CTTCTTGCTA GAAACCTCAA AAAGCTGTGG ACGGGCTTTG
24061 ACGAGCGCAC CGTCGCCTCG GACCTGGCCG AGATCGTCCT CCCCCGAGCG CCTGAGGCAG
24121 ACGCTGAAAG GCGGGCTGCC CGACTTCATG AGCCAGAGCA TGTGCAAAA CTACCGCACT
24181 TTCATTCTCG AGCGATCTGG GATGCTGCCC GCCACCTGCA ACGCCTTCCC CTCCGACTTT
24241 GTCCCGCTGA GCTACCGCGA GTGTCCCCCG CCGCTGTGGA GCCACTGCTA CCTCTTGCA
24301 CTGGCCAACT ACATCGCCTA CCACTCGGAT GTTATCGAGG ACGTGAGCGG CGAGGGGCTG
24361 CTAGAGTGCC ACTGCCGCTG CAACCTGTGC TCTCCGCACC GCTCCTGGTC TGAACCCCC
24421 AGCTCCTGAG CGAGACCCAG GTCATCGGTA CCTTCGAGCT GCAAGGTCCG CAGGAGTCCA
24481 CCGCTCCGCT GAAACTCACG CCGGGGTTGT GGACTTCCGC GTACCTGCGC AAATTTGTAC
24541 CCGAGGACTA CCACGCCCAT GAGATAAAGT TCTTCGAGGA CCAATCGCGC CCGCAGCAGC
24601 CGGATCTCAC GGCTGCGTC ATCACCAGG GCGCGATCCT CGCCCAATTG CACGCCATCC
24661 AAAAATCCCG CCAAGAGTTT CTTTGA AAAA AGGGTAGAGG GGTCTATCTG GACCCCCAGA
24721 CGGGCGAAGT GCTCAACCCG GGTCTCCCC AGCATGCCGA AGAAGAACAG GAGCCGCTAG
24781 TGAAGAAGAT GGAAGAAGAA TGGGACAGCC AGCAGAAGAA GACGAATGGG AAGAAGAGAC
24841 AGAAGAAGAA GAATTGGAAG AGTGAAGAA GAGCAGCACA GACACCGTCG CCGCACCATC
24901 CGCGCCGCGC CCCGGCGGTC ACGGATACAA CTCGCACTCC GCCAAGCTCC TCGTAGATGG
24961 ATCGAGTGAA GGTGACGGTA AGCAGGAGCG GCAGGGCTAC GAATCATGGA GGCCCCACAAA
25021 GCGGGATCAT CGCCTGCTTG CAAGACTGCG GGGGGAACAT CGTTTCGCCC GCCGCTATCT
25081 GCTCTTCCAT CGCGGGGTGA ACATCCCCCG CAACGTGTTG CATTACTACC TCGACCTTCA
25141 CAGCTAAGAA AAAATCAGAG TAAGAGGAGT CGCCGAGGA GGCNTGAGGA TCGCGCGGAA
25201 CGAGCCATTG ACCACCAGGG AGCTGAGGAA TCGGATCTTC CCCACTCTTT ATGCCATTTT
25261 TCAGCAGAGT CGAGGTCAGC AGCAAGAGCT CAAAGTAAAA AACCCTGCTC TCGCTCGCT
25321 CACCCGCACT TGCTTGTAAC AAAAAACGA AGATCAGCTG CAGCGCACTC TCGAAGACGC
25381 CGAGGCTCTG TTCCACAAGT ACTGCGGCT CACTCTTAAA GACTAAGGCG CGCCCACCCG
25441 GAAAAAAGGC GGAATTACC TCATCGCCAC CATGAGCAAG GAGATTCCCA CCCCTTACAT
25501 GTGGAGCTAT CAGCCCCAGA TGGGCTGGC CGCGGGCGCC TCCCAGGACT ACTCCACCCG
25561 CATGAAGTGG CTCAGTGCCG GCCCCTCGAT GATCTCACGG GTCAACGGGG TCCGTAACCA
25621 TCGAAACCAG ATATTGTTGG AGCAGGCGGC GGTACCTCA ACGCCAGGC AAAGCTCAAC
25681 CCGCGTAATT GGCCCTCCAC CCTGGTGTAT CAGGAAATCC CCGGGCCGAC TACCGTACTA
25741 CTTCCGCTG ACGCACCTGC CGAAGTCGCG ATGACTAAT CAGGTGTCCA GCTGGCCGGC
25801 GGCCTTCCC GTGCCCCGCT CCGCCACAA TCGGGTATAA AAACCTGGT GATACGAGC
25861 AGAGGCACAC AGCTCAACGA CGAGTTGGTG AGCTCTTCAA TCGGTCTGCG ACCGGACGGA
25921 GTGTTCCAAC TAGCCGAGC CGGGAGATCG TCCTTCACTC CCAACCAGGC TACCTGACCT
25981 TGCAGAGCAG CTCTTCGGAG CCTCGCTCCG GAGGCATCGG AACCTCCAG TTTGTGGAGG
26041 AGTTTGTGCC CTCGGTCTAC TTCAACCCCT TCTCGGATC GCCAGGCCTC TACCCGAGC
26101 AGTTCATACC GAACTTCGAC GCAGTGAGAG AAGCGGTGGA CGGCCACGAC TGAATGTCTT
26161 ATGGTGAATC GGCTGAGCTC GCTCGGTTGA GGACCTAGA CCACTGCCGC CGCCTGCGCT
26221 GCTTCGCCCC GGAGAGCTGC GGACTTATCT ACTTTGAGTT TCCCAGGAG CACCCCAACG
26281 GCCCTGCACA CGGAGTGCGG ATCACCCTAG AGGGCACCAC CGAGTCTCAC CTGGTTAGGT
26341 TCTTCACCCA GCAACCCCTC CTGGTCGAG GGGACCGGG AGGCACCACC TACACCGTCT
26401 ACTGCTCTG TCCAACCCCG AAGTTGCATG AGAATTTTGT TTGTACTCTG TGTGCTGAGT
26461 TTAATAAAAAG CTAAACTCCT ACAATACTCT GGGATCCCCT GTCGTCCGAC TCGCAACAAG
26521 ACCTTCAACC TCACCAACCA GACTGAGGTA AAATTCAACT GCAGACCGGG GGACAAATAC
26581 ATCCTCTGGC TTTTAAAAA CACTTCCTTC GCAGTCTCCA ACGCCTGCGC CAACGACGGT
26641 ATTGAAATAC CCAACAACCT TACCAGTGGA CTAACCTATA CTACCAGAAA GACTAAGCTA
26701 GACTCTACA ATCCTTTTGT AGAGGGAACC TACCACTGCC AGAGCGGACC TTGCTTCCAC
26761 ACTTTCACCT TGGTGAACGT TACCGACAGC AGCAGCCG CTACAGAAAC ATCTAACCTT
26821 CTTTTTGATA CTAACACTCC TAAAACCGGA GGTGAGCTCT GGGTTCCTC TCTAACAGAG
26881 GGGGGTAAAC ATATTGAAGC GGTGGGTAT TTGATTTTAG GGGTGGTCCT GGGTGGGTGC
26941 ATAGCGGTGC TGTATTACCT TCCTTGCTGG ATCGAAATCA AAATCTTTAT CTGCTGGGTC
27001 AGACATTGTT GGGAGGAACC ATGAAGGGG TCTTGCTGAT TATCCTTTCC CTGGTGGGGG
27061 GTGACTGTAC ATGCCACGAA CAGCCACGAT GTAACATCAC CACAGGCAAT GAGAGGAGTG
27121 TGATATGCAC AGTAGTCATC AAATGCGAGC ATACATGCCC TCTCAACATC ACATTCAAAA
27181 ACCGTACCAT GGGAAATGCA TGGGTGGGCG ACTGGGAACC AGGAGATGAG CAGAACTACA
27241 CGGTCACTGT CCATGGTAGC AATGGAAATC AACTTTTGG TTTCAAATTC ATTTTGAAG
27301 TCATGTGTGA TATCACACTG CATGTGGCTA GACTTCATGG CTTGTGGCCC CCTACCAAGG

27361 ATAACATGGT TGGGTTTTCT TTGGCTTTTG TGATCATGGC CTGTGCAATG TCAGGTCTGC
27421 TGGTAGGGGC TTTAGTGTGG TTCTAAAGC GCAAGCCTAG GTATGGAAT GAGGAGAAGG
27481 AAAAATGCT ATAAATCTTT TCTCTTCGCA GAACCATGAA TACAGTGATC CGTATCGTGC
27541 TGCTCTCTCT TCTTGTAACT TTTAGTCAGG CAGGATTCAT ACCATCAATG CTACATGGTG
27601 GGCTAATATA ACTTTAGTGG GACCTCAGAT ATTCCAGATC ACATGGTATG ATAGCACTGG
27661 ATTGCAATTT TGTGATGGAA GTACAGTTAA GAATCCACAG ATCAGACATA GTTGTAAATGA
27721 TCAAAAACCTA ACTCTGATTC ATGTGAACAA AACCCATGAA AGAACATACA TGGGCTATAA
27781 TAAGCAGAGT ACTCATAAAG AAGACTATAA AGTCACAGTT ATACCACCTC CTCCTGTTAC
27841 TGTAAGGCCA CAACCAGAGC CAGAATATGT GTATGTTAAT ATGGGAGAGA ACAAACCTT
27901 AGTTGGGCCT CCAGGAATTC CAGTTAGTTG GTTTAATCAG GATGGTTTAC AATTTTGACAT
27961 TGGGGATAAA GTTTTTTCATC CAGAATTCAA CCACACCTGT GACATGCAAA ATCTTACACT
28021 GTTGTTTTATA AATCTTACAC ATGATGGAGC TTATCTTGGT TATAATCGCC AGGGAACCTGA
28081 AAGAACCTGG TATGAGGTTG TAGTGTGAGA TGGTTTTCCA AAATCAGAAG AGATGAAGGT
28141 AGAAGACCAT AGTAAAGAAA CAGAACAAAA ACAGACTGGT CAAAAACAAA GTGACCATAA
28201 GCAGGGTGGG CAAAAAGAAA CAAGTCAAAA GAAAACTAAT GACAAACAAA AGCCATCGCG
28261 CAGGAGGCCA TCTAAACTAA AGCCAAACAC ACCTGACACA AAATAATTA CAGTCACTAG
28321 TGGGTCAAAC GTAACCTTAG TTGGTCCAGA TGGAAAGGTC ACTTGGTATG ATGATGATTT
28381 AAAAAGACCA TGTGAGCCTG GGTATAAGTT AGGGTGTAAAG TGTGACAATC AAAACCTAAC
28441 CCTAATCAAT GTAACATAAC TTTATGAGGG AGTTTACTAT GGTACTAATG ACAGAGGCAA
28501 CAGCAAAAGA TACAGAGTAA AAGTAAACAC TACTAATTC TAAAGTGTGA AAATTCAGCC
28561 GTACACCAGG CCTACTACTC CTGATCAGAA ACACAGATTT GAATTGCAAA TTGATTCTAA
28621 TCAAGACAAA ATTCCATCAA CTACTGTGGC AATCGTGGTG GGAGTGATCG CGGGCTTTGT
28681 AACTCTAATC ATTATTTTCA TATGCTACAT CTGCTGCCGC AAGCGTCCCA GGTACATCAA
28741 TCATATGGTA GACCCACTAC TCAGCTTCTC TTAAGTAAAC TCAGTCACTC TCATTTCAGA
28801 ACCATGAAGG CTTTCACAGC TTGCGTTCTG ATTAGCATAG TCACACTTAG TTCAGCTGCA
28861 ATGATTAAATG TTAATGTCAC TAGAGGTGGT AAAATTACAT TGAATGGGAC TTATCCACAA
28921 ACTACATGGA CAAGATATCA TAAAGATGGA TGGAAAAATA TTTGTGAATG GAATGTTACT
28981 GCATACAAAT GCTTCAATAA TGGAAGCATT ACTATTACTG CCACTGCCAA CATTTACTCT
29041 GGCACATACA AAGCTGAAAG CTATAAAAT GAAATTAAAA AATTAACCTA TAAAAACAAC
29101 AAAACCATAT TTGAAGATTC TGGAAATTAT GAGCATCAA AATTATCTTT TTATATGTTG
29161 ACAATAATTG AACTGCCTAC AACCAGGCA CCCACCACAG TTAGTACAAC TACACAGTCA
29221 ACTGTTAAGA CCACTACTCA CACTACACAG CTAGACACCA CAGTGCAGAA TAATACTGTG
29281 TTGGTTAGGT ATTTGTTGAG GGAGGAAAGT ACTACTGAAC AGACAGAGGC TACCTCAAGT
29341 GCCTTTATCA GCACTGCAAA TTTAAGCTTC CTTGCTTGGA CTAATGAAAC CGGAGTATCA
29401 TTGATGCATG GCCAGCCTTA CTCAGGTTTG GATATTCAA TTAATTTTCT GGTGTCTGT
29461 GGGATCTTTA TTCTTGTTGG TCTTCTGTAC TTTGTCTGCT GTAAAGCCAG AAAGAAATCT
29521 AGGAGGCCCA TCTACAGGCC AGTGATTGGG GAACCTCAGC CACTCCAAGT GGATGGAGGC
29581 TTAAGGAATC TTCTTTTCTC TTTTACAGTA TGGTGATCAG CCATGATTCC TAGTCTCTCC
29641 TATTTAACAT CCTCTTCTGT CTCTTCAACA TCTGTGCTGC CTTTGCGGCA GTTTCGCACG
29701 CCTCGCCCGA CTGTCTAGGG CCTTTCCCA CCTACTCCTC TTTGCCCTGC TCACCTGCAC
29761 CTGCGTCTGC AGCATTGTCT GCCTGGTCAT CACCTTCCTG CAGCTCATCG ACTGGTGTG
29821 CGCGCGCTAC AATTACTTCA TCATAGTCCC GAATACAGGG ACGAGAAGT AGCCAGAATT
29881 TTAAGGCTCA TATGACCATG CAGACTCTGC TCATACTGCT ATCGCTCTTA TCCCATGCCC
29941 TCGCTACTGC TGATTACTCT AAATGCAAAT TGGCGGACAT ATGGAATTTT TTAGACTGCT
30001 ATCAGGAGAA AATTGATATG CCCTCCTATT ACTTGGTGAT TGTGGGAATA GTTATGGTCT
30061 GCTCCTGCAC TTTCTTTGCC ATCATGATCT ACCCTGTGTT TGATCTTGGA TGGAACTCTG
30121 TTGAGGCATT CACATACACA CTAGAAAGCA GTTCACTAGC CTCCACGCCA CCACCCACAC
30181 CGCTCCCCG CAGAAATCAG TTTCCCATGA TTCAGTACTT AGAAGAGCCC CCTCCCCGAC
30241 CCCCTTCCAC TGTTAGCTAC TTTACATAAA CCGGCGGCGA TGACTGACCA CCACCTGGAC
30301 CTCGAGATGG ACGGCCAGGC CTCCGAGCAG CGCATCCTGC AACTGCGCGT CCGTCAGCAG
30361 CAGGAGCGTG CCGCCAAGGA GCTCCTCGAT GCCATCAACA TCCACCAAGT CAAGAAGGGC
30421 ATCTTCTGCC TGGTCAAACA GGCAAGATC ACCTACGAGC TCGTGTCCAA CGGCAACAG
30481 CATCGCTTCA CCTATGAGT GCCCAGCAG AAGCAGAAGT TCACCTGCAT GGTGGGCGTC
30541 AACCCCATAG TCATACCCA GAGTCCGGC GAGACCAACG GCTGCATCCA CTGCTCTCTC
30601 GAAAGCCCCG AGTGATCTA CTCCCTTCTC AAGACCCTTT GCGGACTCCG CGACCTCTCTC
30661 CCCATGAACT GATGTTGATT AAAAACCAAA AAAACAATC AGCCCCCTTC CCTATCCCAA
30721 ATTACTCGCA AAAATAAATC ATTGGAACAT ATCATTTAAT AAAGATCACT TACTTGAAT

- 37 -

30781 CTGAAAGTAT GTCTCTGGTG TAGTTGTTCA GCAGCACCTC GGTACCCCTC TCCCAACTCT
30841 GGTACTCCAG TCTCCGGCGG GCGGCGAACT TTCTCCACAC CTTGAAAGGG ATGTCAAATT
30901 CCTGGTCCAC AATTTTCATT GTCTTCCCTC TCAGATGTCA AAGAGGCTCC GGGTGGGAAGA
30961 TGACTIONAAC CCCGTCTACC CCTATGGCTA CGCGCGGAAT CAGAATATCC CCTTCCTCAC
31021 TCCCCCCTTT GTCTCCTCCG ATGGATTCAA AAACCTCCCC CCTGGGGTCC TGTCACCTCAA
31081 ACTGGCTGAC CCAATCACCA TAGCCAATGG TGATGTCTCA CTCAAGGTGG GAGGGGACTT
31141 ACTTTGCAAG AAGGAAGTAT GACTGTAGAC CCTAAGGCTC CCTTGCAACT TGCAAAACAAT
31201 AAAAACTTG AGCTTGTTTA TGTGTATCCA TTTGAGGTTA GTGCCAATAA ACTTAGTTTA
31261 AAAGTAGGAC ATGGATTAAA AATATTAGAT GACAAAAGTG CTGGAGGGTT GAAAGATTTA
31321 ATTGGCAAAC TTGTGGTTTT AACAGGGGAA AGGAATAGGC ACTGAAAATT TGCAAAATAC
31381 AGATGGTAGC AGCAGAGGAA TTGGTATAAG TGTAAAGACA AGAGAAGGGT TAACATTGTA
31441 CAATGATGGA TACTTGGTAG CATGGAACCC AAAGTATGAC ACGCGCACAC TTTGGACAAC
31501 ACCAGACACA TCTCCTAATT GCAGGATTGA TAAGGAGAAG ATTCAAAACT CACTTTGGTA
31561 CTTACAAAGT GTGGAAGTCA AATATTAGCT AATGTGTCTT TGATTGTGGT GTCAGGAAAA
31621 TATCAATACA TAGACCACGC TACAAATCCA ACTCTTAAAT CATTTAAAAT AAAACTTCTT
31681 TTTGATAATA AAGGTGTACT TCTCCCAAGT TCAAACCTTG ATTCCACATA TTGGAACCTT
31741 AGAAGTGACA ATTAACTGT ATCTGAGGCA TATAAAAATG CAGTTGAATT TATGCCTAAT
31801 TTGGTAGCCT ACCCAAAACC TACCACTGGC TCTAAAAAAT ATGCAAGGGA TATAGTCTAT
31861 GGGAACATAT ATCTTGAGG TTTGGCATAT CAGCCAGTTG TAATTAAGGT TACTTTTAAT
31921 GAAGAAGCAG ATAGTGCTTA CTCTATAACA TTTGAATTTG TATGGAATAA AGAATATGCC
31981 AGGGTTGAAT TTGAAACCAC TTCCTTTACC TTCTCCTATA TTGCCCAACA ATAAAGACC
32041 AATAAACGTG TTTTATTATT CAAATTTTAT GTATCTTTAT TGATTTTATC ACCAGCGCGA
32101 GTAGTCAATC TCCCACCACC AGCCCATTTT ACAGTGATACA CGGTCTCTC AGCAGGGTGG
32161 CCTTAAATAA GGAAATGTTT TGATTATTGC GGGAACTGGA CTTGGGGTCT ATAAATCCACA
32221 CAGTTTCTCG ACGAGCCAAA CGGGGATCGG TGATTGAAAT GAAGCCGTCC TCTGAAAAGT
32281 CATCCAAGCG GGCCTCACAG TCCAGGTCAC AGTCTGGTGG AACGAGAAGA ACGCACAGAT
32341 TCATACTCGG AAAACAGGAT GGGTCTGTGC CTCTCCATCA GCGCCCTCAG CAGTCTCTGC
32401 CGCCGGGGCT CGGTGCGGCT GCTGCAAATG GGATCGGGAT CACAAGTCTC TCTAACTATG
32461 ATCCCAACAG CCTTCAGCAT CAGTCTCTCG GTGCGTCTGAG CACAGCACCG CATCTGATC
32521 TCTGCCATGT TCTCACAGTA AGTGCAGCAC ATAATCACCA TGTATTTCAG CAGCCCATAA
32581 TTCAGGGTGC TCCAGCCAAA GCTCATGTTG GGGATGATGG AACCACGTG ACCATCGTAC
32641 CAGATGCGGC AGTATATCAG GTGCCTGCC CTCATGAACA CACTGCCCAT ATACATGATC
32701 CTTTGGGCA TGTTTCTGTT TACAATCTGG CGGTACCAGG GGAAGCGCTG GTTGAACATG
32761 CCCCCGTAAA TGACTCTCCT GAACCACAG GCCAGCAGG TGCCCTCCCG CCGACACTGC
32821 AGGGAGCCAG GGGATGAACA GTGGCAATGC AGGATCCAGC GCTCGTACCC GCTCACCATC
32881 TGAGCTCTTA CCAAGTCCAG GGTAGCGGG CACAGGCACA CTGACATACA TCTTTTAAAA
32941 ATTTTATTTT CCTCTGTGGT GAGGATCATA TCCCAGGGGA CTGGAACTC TTGGAGCAGG
33001 GTAAAGCCAG CAGCACATGG TAATCCACGG ACAGAACTTA CATTATGATA ATCTGCATGA
33061 TCACAATCGG GCAACAGGGG ATGTTGATCA GTCAGTGAAG CCCTGGTTTC ATCATCAGAT
33121 CGTGGTAAAC GGGCCCTGCG ATATGGATGA TGGCGGAGCG AGCTGGATTG AATCTCGGTT
33181 TGCATTGTAG TGGATTCTCT TGCGTACCTT GTCGTACTTC TGCCAGCAGA AATGGGCCCT
33241 TGAACAGCAT ATACCCCTCC TGCGGCCGTC CTTTCGCTGC TGCCGCTCAG TCATCCAACT
33301 GAAGTACATC CATTCTCGAA GATTCTGGAG AAGTTCCTCT GCATCTGATG AAATAAAAAA
33361 CCCGTCCATG CGAATTCCCC TCATCACATC AGCCAGGACT CTGTAGGCAA TCCCCATCCA
33421 GTTAATGCTG CTTGTCTAT CATTACAGAG GGGCGGTGCG AGGATTGGAA GAACCATTTT
33481 TATTCCAAAC GGTCTCGAAG GACGATAAAG TGCAAGTCAC GCAGGTGACA GCGTTCCCTT
33541 CCGCTGTGCT GGTGGAAACA GACAGCCAGG TCAAAACCCA CTCTATTTTC AAGGTGCTCG
33601 ACCGTGGCTT CGAGCAGTGG CTCTACGCGT ACATCCAGCA TAAGAATCAC ATTAAGGCT
33661 GGGCCCTCCAT CGATTTTCATC AATCATCAGG TTACATTCTT GCACCATCCC CAGGTAATTC
33721 TCATTTTTTCC AGCCTTGGAT TATCTCTACA AATTGTTGGT GTAAATCCAC TCCGCACATG
33781 TTGAAAAGCT CCCACAGTGC CCCCTCCACT TTCATAATCA GGCAGACCTT CATAATAGAA
33841 ACAGATCCTG CTGCTCCACC ACCTGCAGCG TGTTCAAAAC AACAGATTTC AATAAGGTTT
33901 TGCCCTCCGC CCTGAGCTCG CGCCTCAATG TCAGCTGCAA AAAGTCACTT AAGTCTGGG
33961 CCACTACAGC TGACAATTCA GAGCCAGGG TAAGCGTGGG ACTGGCAAGC GTGAGGAAAA
34021 ACTTTAATGC TCCAAAGCTA GCACCCAAAA ACTGCATGCT GGAATAAGCT CTCCTTGTGT
34081 TCCCGGTGAT GCCTTCCAAA ATGTGAGTGA TAAAGCGTGG TAGTTTTTTC TTTAATCATT
34141 TGCGTAATAG AAAAGTCTCG TAAATAAGTC ACTAGGACCC CAGGGACCAC AATGTGGTAG

- 38 -

34201 CTTACACCGC GTCGCTGAAA GCATGGTTAG TAGAGATGAG AGTCTGAAAA ACAGAAAGCA
34261 TGCCTGCTAAC TAAGGTGGCT ATTTTCACTG AAGGAAAAAT CACTCTTTCC AGCAGCAGGG
34321 TACCCACTGG GTGGCCCTTG CGGACATACA AAAATCGGTC CGTGTGATTA AAAAGCAGCA
34381 CAGTAAGTTC CTGTCTTCTT CCGGCAAAAA TCACATCGGA CTGGGTAGT ATGTCCCTGG
34441 CATGGTAGTC ATTCAAGGCC ATAAATCTGC CCTGATATCC AGTAGGAACC AGCACACTCA
34501 CTTTTAGGTG AAGCAATACC ACCCCATGCG GAGGAATGTG GAAAGATTCA GGGCAAAAAA
34561 AATTATATCT ATTGCTAGCC CTTCTGGAC GGGAGCAATC CTCCAGGACT ATCTATGAAA
34621 GCATACAGAG ATTCAGCCAT AGCTCAGCCC GCTTACCAGT AGACAAAGAG CACAGCAGTA
34681 CAAGCGCCAA CAGCAGCGAC TGACTACCCA CTGACTTAGC TCCCTATTTA AAGGCACCTT
34741 ACACTGACGT AATGACCAA GGTCTAAAAA CCCC GCCAAA AAAACACACA CGCCCTGGGT
34801 GTTTTTCGGA AAACACTTCC GCGTTCTCAC TTCCTCGTAT CGATTTCGTG ACTTGACTTC
34861 CGGGTTCCCA CGTTACGTCA CTTTGGCCCT TACATGTAAC TTAGTCGTAG GGCGCCATCT
34921 TGCCACGTC CAAAATGGCT TACATGTCCA GTTACGCCTC CGCGCGGACC GTTAGCCGTG
34981 CGTCGTGACG TCATTTGCAT CAACGTTTCT CGGCCAATCA GCAGTAGCCC CGCCCTAAAT
35041 TTAAAACCTC ATTTGCATAT TAACTTTGTG TTACTTTGTG GGGTATATTA TTGATGATG

ATGTCAAAGAGGCTCCGGGTGGAAGATGACTTCAACCCCGTCTACCCCTA
TGGCTACGCGCGGAATCAGAATATCCCCTTCCTCACTCCCCCCTTTGTCTC
CTCCGATGGATTCAAAAACCTTCCCCCCTGGGGTCCTGTCACTCAAACCTGGC
TGACCCAATCACCATAGCCAATGGTGATGTCTCACTCAAGGTGGGAGGGG
GACTTACTTTGCAAGAAGGAAGTCTGACTGTAGACCCTAAGGCTCCCTTG
CAACTTGCAAACAATAAAAAACCTTGAGCTTGTTTATGTTGATCCATTTGAG
GTTAGTGCCAATAAACTTAGTTTTAAAAGTAGGACATGGATTAAAAATATT
AGATGACAAAAGTGCTGGAGGGTTGAAAGATTTAATTGGCAAACCTTGTTG
TTTTAACAGGGAAAGGAATAGGCACTGAAAATTTGCAAATACAGATGGT
AGCAGCAGAGGAATTGGTATAAGTGTAAGAGCAAGAGAAGGGTTAACAT
TTGACAATGATGGATACTTGGTAGCATGGAACCCAAAGTATGACACGCGC
ACACTTTGGACAACACCAGACACATCTCCTAATTGCAGGATTGATAAGGA
GAAGGATTCAAAACCTCACTTTGGTACTTACAAAGTGTGGAAGTCAAATAT
TAGCTAATGTGTCTTTGATTGTGGTGTGAGGAAAATATCAATACATAGACC
ACGCTACAAATCCAACCTCTTAAATCATTTAAAATAAACTTCTTTTTGATA
ATAAAGGTGTACTTCTCCCAAGTTCAAACCTTGATTCCACATATTGGAACCT
TTAGAAGTGACAATTTAACTGTATCTGAGGCATATAAAAATGCAGTTGAA
TTTATGCCTAATTTGGTAGCCTACCCAAAACCTACCACTGGCTCTAAAAAA
TATGCAAGGGATATAGTCTATGGGAACATATATCTTGGAGGTTTGGCATA
TCAGCCAGTTGTAATTAAGGTTACTTTTAATGAAGAAGCAGATAGTGCTTA
CTCTATAACATTTGAATTTGTATGGAATAAAGAATATGCCAGGGGTTGAA
TTTGAAACCACTTCCTTTACCTTCTCCTATATTGCCCAACAATAA

SEQ ID NO:2

SUBSTITUTE SHEET (RULE 26)

Penton17.Seq Length: 1554

```
1  ATGAGGCGTG CGGTGGTGTC TTCCTCTCCT CCTCCCTCGT ACGAGAGCGT
51  GATGGCGCAG GCGACCCTGG AGGTTCCGTT TGTGCCTCCG CGGTATATGG
101 CTCCTACGGA GGGCAGAAAC AGCATTCGTT ACTCGGAGCT GGCTCCGTTG
151 TACGACACCA CTCGCGTGTA CTTGGTGGAC AACAAGTCGG CGGACATCGC
201 TTCCCTGAAC TATCAAAACG ACCACAGCAA CTTCTTGACC ACGGTGGTGC
251 AGAACAACGA TTTACCCCC GCCGAGGCTA GCACGCAGAC GATAAATTTT
301 GACGAGCGGT CGCGGTGGGG CGGTGATCTG AAGACCATTC TGCACACCAA
351 CATGCCCAAT GTGAACGAGT ACATGTTTAC CAGCAAGTTT AAGGCGCGGG
401 TGATGGTGGC TAGAAAACAC CCACAGGGGG TAGAAGCAAC AGATTTAAGC
451 AAGGATATCT TAGAGTATGA GTGGTTTGAG TTTACCCTGC CCGAGGGCAA
501 CTTTTCCGAG ACCATGACCA TAGACCTGAT GAACAACGCC ATCTTGGA
551 ACTACTTGCA AGTGGGGCGG CAAAATGGCG TGCTGGAGAG CGATATTGGA
601 GTCAAGTTTG ACAGCAGAAA TTTCAAGCTG GGCTGGGACC CTGTGACCAA
651 GCTGGTGATG CCAGGGGTCT ACACCTACGA GGCCTTTCAC CCGACGTGG
701 TGCTGCTGCC GGGCTGCGGG GTGGACTTCA CAGAGAGCCG CCTGAGCAAC
751 CTCCTGGGCA TTCGCAAGAA GCAACCTTTC CAAGAGGGCT TCAGAATCAT
801 GTATGAGGAT CTAGAAGGGG GCAACATCCC CGCCCTGCTG GATGTGCCCCA
851 AGTACTTGGA AAGCAAGAAG AAGTTAGAGG AGGCATTGGA GAATGCTGCT
901 AAAGCTAATG GTCCTGCAAG AGGAGACAGT AGCGTCTCAA GAGAGGTTGA
951 AAAGGCAGCT GAAAAAGAAC TTGTTATTGA GCCCATCAAG CAAGATGATA
1001 CCAAGAGAAG TTACAACCTC ATCGAGGGAA CCATGGACAC GCTGTACCGC
1051 AGCTGGTACC TGTCTATAC CTACCGGGAC CCTGAGAACG GGGTGCAGTC
1101 GTGGACGCTG CTCACCAACC CGGACGTCAC CTGCGGCGCG GAGCAAGTCT
1151 ACTGGTCGCT GCCGGACCTC ATGCAAGACC CCGTCACCTT CCGTTCTACC
1201 CAGCAAGTCA GCAACTACCC CGTGGTCGGC GCCGAGCTCA TGCCCTTCCG
1251 CGCCAAGAGC TTTTACAACG ACCTCGCCGT CTA TCTCCAG CTCATCCGCA
1301 GCTACACCTC CCTCACCCAC GTCTTCAACC GCTTCCCCGA CAACCAGATC
```

SEQ ID NO: 3

1351 CTCTGCCGTC CGCCCGCGCC CACCATCACC ACCGTCAGTG AAAACGTGCC
1401 TGCTCTCACA GATCACGGGA CGCTACCGCT GCGCAGCAGT ATCCGCGGAG
1451 TCCAGCGAGT GACCGTCACT GACGCCCCTC GCCGCACCTG TCCCTACGTC
1501 TACAAGGCCC TGGGCATAGT CGCGCCGCGT GTGCTTTCCA GTCGCACCTT
1551 CTAA

- 42 -

Claims

1. A chimeric adenoviral vector comprising nucleotide sequence of a first
adenovirus, wherein at least one gene of said first adenovirus encoding a
5 protein that facilitates binding of said vector to a target mammalian cell, or
internalization thereof within said cell, is replaced by the corresponding gene
from a second adenovirus belonging to subgroup D, said vector further
comprising a transgene operably linked to a eucaryotic promoter to allow for
expression therefrom in a mammalian cell.
- 10 2. A chimeric adenoviral vector according to Claim 1 wherein said second
adenovirus is selected from the group consisting of Ad 9, Ad 15, Ad 17, Ad
19, Ad 20, Ad 22, Ad 26, Ad 27, Ad 28, Ad 30, and Ad 39.
- 15 3. A chimeric adenoviral vector according to Claim 1 wherein said first
adenovirus is selected from the group consisting of Ad 2, Ad 5, and Ad 12.
4. A chimeric adenoviral vector according to Claim 1 wherein said replaced gene
encodes Ad fiber.
- 20 5. A chimeric adenoviral vector according to Claim 1 wherein said replaced gene
encodes Ad penton base.
6. A chimeric adenoviral vector according to Claim 1 wherein a first replaced
25 gene encodes Ad fiber, and a second replaced gene encodes Ad penton base.
7. A chimeric adenoviral vector comprising nucleotide sequence of a first
adenovirus, wherein a portion of a gene thereof encoding a protein that
facilitates binding of said vector to a target mammalian cell, or internalization

- 43 -

thereof within said cell, is replaced by a portion of the corresponding gene from a second adenovirus belonging to subgroup D, said vector further comprising a transgene operably linked to a eucaryotic promoter to allow for expression therefrom in a mammalian cell.

5

8. A chimeric adenoviral vector according to Claim 7 wherein the encoding sequence that is replaced codes for a portion of Ad fiber.

9. A chimeric adenoviral vector according to Claim 7 wherein the encoding
10 sequence that is replaced codes for a portion of Ad penton base.

10. A chimeric adenoviral vector according to Claim 9 wherein the encoding sequence that is replaced codes for an amino acid sequence that includes RGD.

15 11. A method of providing a biologically active protein to the airway epithelial cells of a patient comprising administering to said cells an adenoviral vector selected from the group consisting of:

(a) a chimeric adenoviral vector comprising nucleotide sequence of a first adenovirus, wherein at least one gene of said first adenovirus
20 encodes a protein that facilitates binding of said vector to a target mammalian cell, or internalization thereof within said cell, is replaced by the corresponding gene from a second adenovirus belonging to subgroup D, said vector further comprising a transgene encoding said protein that is operably linked to a eucaryotic promoter to allow for
25 expression therefrom in a mammalian cell; and

(b) a chimeric adenoviral vector comprising nucleotide sequence of a first adenovirus, wherein a portion of a gene thereof encoding a protein that facilitates binding of said vector to a target mammalian cell, or internalization thereof within said cell, is replaced by a portion of the

- 44 -

corresponding gene from a second adenovirus belonging to subgroup D, said vector further comprising a transgene encoding said protein that is operably linked to a eucaryotic promoter to allow for expression therefrom in a mammalian cell;


5 under conditions whereby the transgene encoding said protein is expressed, and phenotypic benefit is produced in said airway epithelial cells.

12. A method according to Claim 11 wherein said second adenovirus is Ad 17 and the nucleotide sequence thereof used in replacement of nucleotide sequence of
10 said first adenovirus encodes a polypeptide selected from the group consisting of Ad 17 fiber, a fragment of Ad 17 fiber, Ad 17 hexon, a fragment of Ad 17 hexon, Ad penton base, and a fragment of Ad 17 penton base.

13. A method of providing a biologically active protein to the airway epithelial
15 cells of a patient that comprises administering to said cells an adenoviral vector comprising elements of an Ad 17 genome, and a transgene encoding said protein that is operably linked to a eucaryotic promoter to allow for expression therefrom in a mammalian cell, under conditions whereby the transgene encoding said protein is expressed, and phenotypic benefit is
20 produced in said airway epithelial cells.


1/28

FIG. 1




2/28

FIG. 2



3/28



4 / 28

Chimeric Ad2/ β gal-2/ Ad17 vectors

FIG. 4




FIG. 5A-1

```

| M R R A V V S S P P P S Y E S V M A . . . . . Q A T L E V P F V P P P R Y M A P T E G R 39 SEQ ID NO:4
| | : . . : | | | | | | | | : | . : . | | | | | | | : | | : | |
| M 0 R A A M Y E E G P P P S Y E S V S A A P V A A A L G S P F D A P L D P P F V P P R Y L R P T G G R 52 SEQ ID NO:5

40 N S I R Y S E L A P L Y D T T R V Y L V D N K S A D I A S L N Y Q N D H S N F L T T V V Q N N D F T 89
| | | | | | | | | | : | | | | | | | | | | : | | | | | | | | : | | : .
53 N S I R Y S E L A P L F D T T R V Y L V D N K S T D V A S L N Y Q N D H S N F L T T V I Q N N D Y S 102

90 P A E A S T Q T I N F D E R S R W G G D L K T I L H T N M P N V N E Y M F T S K F K A R V M V A R K 139
| : | | | | | | | | : | | : | | | | | | | | | | : | | | | | | | . | .
103 P G E A S T Q T I N L D D R S H W G G D L K T I L H T N M P N V N E F M F T N K F K A R V M V S R S 152

1140 H P Q G V E A T D L S K D I L E Y E W F E F T L P E G N F S E T M T I D L M N N A I L E N Y L Q V G 189
. . : . . : | . | | | . | | | | | | | | : | | | | | | | | : | | : | |
1153 L T K D K Q V E . . . . . L K Y E W V E F T L P E G N Y S E T M T I D L M N N A I V E H Y L K V G 196

1190 R Q N G V L E S D I G V K F D S R N F K L G W D P V T K L V M P G V Y T Y E A F H P D V V L L P G C 239
| | | | | | | | | | . | | : | | : | | | | | | | | | | | | | | : | | | | |
1197 R Q N G V L E S D I G V K F D T R N F R L G F D P V T G L V M P G V Y T N E A F H P D I I L L P G C 246

```


FIG. 6A-1

8/28

1
 Penton5 ... MRRAAM. YEEGP PPSYESVSA .. APVAAALG SPFDAPLDPP~SEQ ID NO:6
 Penton2 ... MQRAAM. YEEGP PPSYESVSA .. APVAAALG SPFDAPLDPP~SEQ ID NO:5
 Penton3 .. MRRRAVLG GAV.VYPEGP PPSYESVM.. QQQA AMIQPPLEAP~SEQ ID NO:7
 Penton12 ... MRRRAVEL QTV.AFPETP PPSYETVM.. AAAPP~SEQ ID NO:8
 Penton40 ... MRRRAVG PVVMAYAE GP PPSYESVM.. ET ADLPATLQAL~SEQ ID NO:9
 Penton17 ... MRRRAVV. SSSP PPSYESVM.. A... .. QATLEVP~SEQ ID NO:4
 Pentonf10 MWGLQPPTSI PPPPPPTTELT PSTYPAMVNG YPPPAASAQS CSSSGGQSEL~SEQ ID NO:10

51
 Penton5 FVP.PRYLRP TGGRNSIRYS ELAPLEDTTR VYLVDNKSTD VASLNYQNDH
 Penton2 FVP.PRYLRP TGGRNSIRYS ELAPLEDTTR VYLVDNKSTD VASLNYQNDH
 Penton3 FVP.PRYLAP TEGRNSIRYS DVSPLYDTTK LYLVDNKSD IASLNYQNDH
 Penton12 YVP.PRYLGP TEGRNSIRYS ELSPLYDTTR VYLVDNKSSD IASLNYQNDH
 Penton40 HVP.PRYLGP TEGRNSIRYS ELAPLYDTTR VYLVDNKSD IASLNYQNDH
 Penton17 FVP.PRYMAP TEGRNSIRYS ELAPLYDTTR VYLVDNKSD IASLNYQNDH
 Pentonf10 YMPLQVRMAP TGGRNSIKYR DYTPCRNTTK LFYVDNKASD IDTYNKKDANH

FIG. 6A-2

101 150

Penton5	SNFLTTVIQN	NDYSPGEAST	QTINLDDRSR	WGGDLKTIH	TNMPNVNEFM
Penton2	SNFLTTVIQN	NDYSPGEAST	QTINLDDRSR	WGGDLKTIH	TNMPNVNEFM
Penton3	SNFLTTVVQN	NDFTPT EAST	QTINFDESR	WGGQLKTIH	TNMPNVNEYM
Penton12	SNFLTTVVQN	NDYSPIEAGT	QTINFDESR	WGGDLKTIH	TNMPNVNDFM
Penton40	SNFQTTVVQN	NDFTPT EAGT	QTINFDDRSR	WGGDLKTIH	TNMPNINEFM
Penton17	SNFLTTVVQN	NDFTPAEAST	QTINFDESR	WGGDLKTIH	TNMPNVNEYM
Pentonf10	SNFRTTVIHN	QDLADTAAT	ESIQLDNRSC	WGGDLKTAVR	TNCPNVSSFF

200 9/28

151

Penton5	FTNKFKARVM	VSRL.....	...PTKD..N	QVELKYEWVE	FTLPEGNYSE
Penton2	FTNKFKARVM	VSRS.....	...LTKD..K	QVELKYEWVE	FTLPEGNYSE
Penton3	FSNKFKARVM	VSRAPEGVT	VNDTYDH..K	EDILKYEWFE	FILPEGNFSA
Penton12	FTTKFKARVM	VARK.....	...TNNE..G	QTILEYEWAE	FVLPEGNYSE
Penton40	STNKFRARVM	VEK.....VNR..K	TNAPRYEWFE	FTLPEGNYSE
Penton17	FTSKFKARVM	VARKHPQGV.	..EATDL..S	KDILEYEWFE	FTLPEGNFSE
Pentonf10	QSNSVRVRMM	WKRDPPTSTA	PPSAVSGSYS	VPGAQYKWD	LTVPEGNYAL

201 250

Penton5	TMTIDLMNNA	IVEHYLKVGR	QNGVLESDIG	VKFDTRNFR	GFDPVTGLVM
---------	------------	------------	------------	-----------	------------

10 / 28

FIG. 6B-1

Penton2	TMTIDLMNNA	IVEHYLKVGR	QNGVLESDIG	VKFDTRNFRL	GFDPVTGLVM
Penton3	TMTIDLMNNA	IIDNYLEIGR	QNGVLESDIG	VKFDTRNFRL	GWDPETKLIM
Penton12	TMTIDLMNNA	IIEHYLRVGR	QHGVLESDIG	VKFDTRNFRL	GWDPETQLVT
Penton40	TMTIDLMNNA	IVDNYLAVGR	QNGVLESDIG	VKFDTRNFRL	GWDPVTKLVM
Penton17	TMTIDLMNNA	I LENYLQVGR	QNGVLESDIG	VKFDSRNFKL	GWDPVTKLVM
Pentonf10	CELIDLLNEG	IVQLYLSEGR	QNNVQKSDIG	VKFDTRNFGL	LRDPVTGLVT
	251				300
Penton5	PGVYTNEAFH	PDIILLPGCG	VDFTHSRLSN	LLGIRKRQPF	QEGFRITYDD
Penton2	PGVYTNEAFH	PDIILLPGCG	VDFTHSRLSN	LLGIRKRQPF	QEGFRITYDD
Penton3	PGVYTYEAFH	PDIVLLPGCG	VDFTESRLSN	LLGIRKRHPF	QEGFKIMYED
Penton12	PGVYTNEAFH	PDIVLLPGCG	VDFTESRLSN	ILGIRKRQPF	QEGFVIMYEH
Penton40	PGVYTNEAFH	PDIVLLPGCG	VDFEQSRLNN	LLGIRKRMPF	QKGFQIMYED
Penton17	PGVYTYEAFH	PDVLLPGCG	VDFTESRLSN	LLGIRKKQPF	QEGFRIMYED
Pentonf10	PGTYVYKGYH	PDIVLLPGCA	IDFTYSRLSL	LLGIGKREPY	SKGFVITYED

11/28

FIG. 6B-2

	301								350
Penton5	LEGGNIPALL	DVDAYQASLK	DDTEQGGGA	GGNSSGGA	EENSNA	AAAAA			
Penton2	LEGGNIPALL	DVDAYQASLK	DDTEQGGGA	GGNSSGGA	EENSNA	AAAAA			
Penton3	LEGGNIPALL	DVTAYEESKK	DTTETTTLA	VAETSE...					
Penton12	LEGGNIPALL	DVKKYENSL.Q.....						
Penton40	LEGGNIPALL	DVEKYEASIK						
Penton17	LEGGNIPALL	DVPKYLESKK	KLE.....E	ALENAAK					
Pentonf10	LQGGDIPALL	DLDSVDVND	A.....						
	351								400
Penton5	MQPVEDMNDH	AIRGDTFATR	AEEKRAEAEA	AAEAAAPAAQ	PEVEKPQKKP				
Penton2	MQPVEDMNDH	AIRGDTFATR	AEEKRAEAEA	AAEAAAPAAQ	PEVEKPQKKP				
Penton3DDD	ITRGDTYITE	KQKREAAAE	V.....KKEL				
Penton12DQN	TVRGDNFIA.L.....	NKAA				
Penton40EAQ	EIRGADFKPN	PQ.....	DL				
Penton17ANG	PARGDSSVR	EVEKAA....	EKEL				
Pentonf10				

FIG 6B-3

12/28

401
 Penton5 VIKPLTEDSK KRSYNLI... SNDSTFTQYR SWLAYNYGD PQTGIRSWTL 450
 Penton2 VIKPLTEDSK KRSYNLI... SNDSTFTQYR SWLAYNYGD PQTGIRSWTL
 Penton3 KIOPLEKDSK SRSYNVL... E.DKINTAYR SWLSYNYGN PEKGIRSWTL
 Penton12 RIEPVETDPK GRSYNLL... P.DKKNTKYR SWLAYNYGD PEKGVRSWTL
 Penton40 EIVPVEKDSK ERSYNLL... EGDKNNTAYR SWFLAYNYGD AEKGVKSWTL
 Penton17 VIEPIKQDDT KRSYNLI... E.GTMDTLYR SWLSYTYRD PENGVSQSWTL
 Pentonf10 ... PLLHDSA GVSYNVIYDQ VTGKPVTAIR SWMLAYNVPN SQANQT..TL

451
 Penton5 LCTPDVTCGS EQVYWSLPDM MQDPVTFRST RQISNFPVVG AELLPVHSHS 500
 Penton2 LCTPDVTCGS EQVYWSLPDM MQDPVTFRST SQISNFPVVG AELLPVHSHS
 Penton3 LTTSDVTCGA EQVYWSLPDM MQDPVTFRST RQVNNYPVVG AELMPVFSKS
 Penton12 LTTPDVTCGS EQVYWSLPDM MQDPVTFRST RQVSNYPVVA AELLPVHSHS
 Penton40 LTTTDVTCGS QQVYWSLPDM MQDPVTFRPS TQVSNYPVVG VELLPVHSHS
 Penton17 LTTPDVTCGA EQVYWSLPDL MQDPVTFRST QQVSNYPVVG AELMPFRSHS
 Pentonf10 LTVPDMAGGI GAMYTSLPDT FIAPTGFKEE NTTNLCPVVG MNLFPTYNKI

501
 Penton5 FYNDQAVYSQ LIRQFT.SLT HVFNRFPENQ ILARPPAPTI TTVSENVVPAL
 Penton2 FYNDQAVYSQ LIRQFT.SLT HVFNRFPENQ ILARPPAPTI TTVSENVVPAL
 Penton3 FYNEQAVYSQ QLRQAT.SLT HVFNRFPENQ ILIRPPAPTI TTVSENVVPAL
 Penton12 FYNEQAVYSQ LIRQST.ALT RVFNRFPENQ ILVRPPAATI TTVSENVVPAL

13/28

FIG. 6C

Penton40	FYNEQAVYSQ	LIRQST.ALT	HIFNRFPENQ	ILVRPPAPTI	TTVSENVPAL
Penton17	FYNDLAVYSQ	LIRSYT.SLT	HVFNRFPDNQ	ILCRPPAPTI	TTVSENVPAL
Pentonf10	YYQAASTYVQ	RLENSCQSAT	AAFNRFPENE	ILKQAPPMNV	SSVCDNQPAV
	551				600
Penton5	TDHGTLP L R N	SIGGVQRVTI	TDARRRTC PY	VYKALGIVSP	RVLSSRTF*
Penton2	TDHGTLP L R N	SIGGVQRVTI	TDARRRTC PY	VYKALGIVSP	RVLSSRTF*
Penton3	TDHGTLP L R S	SIRGVQRVTV	TDARRRTC PY	VYKALGIVAP	RVLSSRTF*
Penton12	TDHGTLP L R S	SISGVQRVTI	TDARRRTC PY	VYKALGIVSP	RVLSSRTF*
Penton40	TDHGTLP L R S	SISGVQRVTI	TDARRRTC PY	VHKALGIVAP	KVLSSRTF*
Penton17	TDHGTLP L R S	SIRGVQRVTV	TDARRRTC PY	VYKALGIVAP	RVLSSRTF*
Pentonf10	VQQGVLPVKS	SLPGLQRVLI	TDDQRRRPIPY	VYKSIATVQP	TVLSSATLQ*

SUBSTITUTE SHEET (RULE 26)

15/28

FIG. 7A-2

```

145 .....NLQNTD...GSSRGIGISVRARE 164
    |::||. ....|:::.....|
301 YNRGLYLENASNNTKKLEVSIIKKSSGLNFDNTAIAINAGKGLEFDTNTSE 350
    |::||. ....|:::.....|
165 .....GLTFDNDGYLVAWNPKYDTRT 185
    ||::||. |::|..|..|..|
351 SPDINPIKIGSGIDYNENGAMITKLGAGLSFDNSGATTIGNKNDDKLT 400
    |::||. ....|:::.....|
186 LWTTPDTSPNCRIDKEKDSKLTLLVLTCKCGSQILANVSLIVVSGKYQYIDH 235
    ||::||. ....|:::.....|
401 LWTTPDPSPNCRIHSDNDCKFTLLVLTCKCGSQVLATVAALAVSGDLS... 446

```


17/28

FIG. 8A-1

8fiber	1	MTKRLRA...	...	EDDFN	PVYPYGYARN	Q.NIPFLTPP	FVSSNGFQNF
9fiber		MSKRLRV...	...	EDDFN	PVYPYGYARN	Q.NIPFLTPP	FVSSDGFQNF
15fiber		MSKRLRV...	...	EDDFN	PVYPYGYARN	Q.NIPFLTPP	FVSSDGFQNF
17fiber		MSKRLRV...	...	EDDFN	PVYPYGYARN	Q.NIPFLTPP	FVSSDGFQNF
2fiber		.MKRARP...	...	SEDTFN	PVYPYDTETG	PPTVPFLTPP	FVSPNGFQES
5fiber		.MKRARP...	...	SEDTFN	PVYPYDTETG	PPTVPFLTPP	FVSPNGFQES
4fiber		MSKSARG...	...	WSDGFD	PVYPYDADND	RP.CPSSTLP	SFSSDGFQEK
40-1fiber		.MKRTRIE...	...	DDFN	PVYPYD.TSS	TPSIPYVAPP	FVSSDGLQEN
41fiber		.MKRTRIE...	...	DDFN	PVYPYD.TFS	TPSIPYVAPP	FVSSDGLQEK
40-2fiber		.MKRARFE...	...	DDFN	PVYPYE.HYN	PLDIPFITPP	FASSNGLQEK
12fiber		.MKRSRTQYA	EETEENDDFN	PVYPFD.PFD	TSDVPFVTPP	FTSSNGLQEK	
3fiber		MAKRARL...	...	STSFN	PVYPYEDESS	SQH.PFINPG	FISPDGFTQS

FIG. 8A-2

8fiber	51	PPGVLSLKLA	DPTIN.NQN	VSLKVGGLT	LQEET	100	SEQ ID NO:13
9fiber		PPGVLSLKLA	DPIAIV.NGN	VSLKVGGLT	LQDGT		SEQ ID NO:14
15fiber		PPGVLSLKLA	DPIAIA.NGN	VSLKMGGLT	LQEGT		SEQ ID NO:15
17fiber		PPGVLSLKLA	DPTIA.NGD	VSLKVGGLT	LQE		SEQ ID NO:11
2fiber		PPGVLSLRVS	EPLDTS.HGM	LALKMGGLT	LDKAGNLT		SEQ ID NO:12
5fiber		PPGVLSLRVS	EPLVTS.NGM	LALKMGGLT	LDEAGNLT		SEQ ID NO:16
4fiber		PLGVLSLPG	RPCHTK.NGE	ITLKLGEVD	LDDSGKL		SEQ ID NO:17
40-1fiber		PPGVLSLKYT	DPTTNKHE	LTLKLGSNIT	LQ.NGLLSA		SEQ ID NO:18
41fiber		PPGVLSLKYT	DPTTNKHE	LTLKLGSNIT	LE.NGLLSA		SEQ ID NO:19
40-2fiber		PPGVLSLKYT	DPLTTK.NGA	LTLKLGTGLN	IDKNGDLSSD		SEQ ID NO:20
12fiber		PPGVLSLKYT	DPIVTE.NGT	LTLKLGDGK	LNAQGLTAS		SEQ ID NO:21
3fiber		PNGVLSLKCV	NPLTTA.SGS	LQLKVGGLT	VD		SEQ ID NO:22
8fiber	101					150	
9fiber							
15fiber							
17fiber							

FIG. 8B-1

2fiber	KTKSNISLDT	FAPLTITSGA	LTVATTAPLI	VTSGALSVQS	QAPLTVQDSK	
5fiber	KTKSNINLEI	SAPLTVTSEA	LTVAAAAPLM	VAGNTLTMQS	QAPLTVHDSK	
4fiber	SFFQQH	HFPL.....	
40-1fiber	
41fiber	
40-2fiber	KTNKIVGLNY	TKPLALQNN	LTLSYNAPFN	VVNNNLALNM	SQPVTI.....	
12fiber	NTSQGLKLSW	SAPLAVKASA	LTLNTRAPLT	TTDESLALIT	APPITVRESSR	
3fiber	
	151				200	
8fiber	19/28
9fiber
15fiber
17fiber
2fiber	LSI
5fiber	LSI
4fiber
40-1fiber
41fiber
40-2fiber	NANNELSLL	IDAPLNADTG	TLRLRSDAPL	GLVDK.TLKV	
12fiber	LGLATIAPLS	LDGGGNLGLN	LSAPLDVSNN	NLHLTTETPL	VVNSSGALSV	
3fiber

FIG. 8B-2

201	8fiber	GKLT	VNTEPLH..	250
	9fiber	GKLT	VNADPPLQ..	
	15fiber	GKLT	VNTEPPLQ..	
	17fiber	GKLT	VDPKAPLQ..	
	2fiber	ATKGPI TVSD	GKLALQTSAP	LSGSDSDTLT	VTASPPPLTTA	TGSLGINMED	
	5fiber	ATQGPLTVSE	GKLALQTSAP	LTSTDSSSTLT	ITASPPPLTTA	TGSLGIDLKE	
	4fiberTWIP	LYTPKMENYP	YKFLPPLSIL	KSTI.....	
	40-1fiber	TVPT	VSPPLTNS	NNSLGLATSA	
	41fiber	TVPT	VSPPLTNS	NNSLGLATSA	
	40-2fiber	LFSSPLYLDN	NFLTALIERP	LALSSNRAVA	LKYSPPPLKIE	NENLTLSTGG	
	12fiber	ATADPISVRN	NALTLPTADP	LMVSSD.GLG	ISVTSPITVI	NGSLALSTTA	
	3fiber	

FIG. 8B-3

8fiber	251	..LTNN.KLG	IALDAPFDVI	D..NKLTLLA	GHGLSII.TK	ETSTLPGLVN	300
9fiber		..LTNN.KLG	IALDAPFDVI	D..NKLTLLA	GHGLSII.TK	ETSTLPGLRN	
15fiber		..LTNN.RIG	IALDAPFDVI	G..GKLTLLA	GHGLSII.TE	ETSPLPGLVN	
17fiber		..LANKKLE	LVYVDPFEVS	A..NKLSLV	GHGLKILDDK	SAGGLKDLIG	
2fiber		PIYVNNKGIG	IKISGPLQVA	QNSDTLTVVT	GPGVTVEQNS	LRTKVAGAIG	
5fiber		PIYTQNGKLG	LKYGAPLHVT	DDLNTLTVAT	GPGVTINNTS	LQTKVTGALG	
4fiber	LNTLVSAF	GSGLGLSGSA	LAVQLASPLT	21/28
40-1fiber		PIAVSANSALT	LATAAPLTVS	N..NQLSINT	GRGLVITNNA	VAVNPTGALG	
41fiber		PIAVSANSALT	LATAAPLTVS	N..NQLSINA	GRGLVITNNA	LTVNPTGALG	
40-2fiber		PFTVSGGNLN	LATSAPLSVQ	N..NSLSLV	NPPFLITDSG	LAMDLDGDLA	
12fiber		PLNSTGSTLS	LSVANPLTIS	Q..DTLTVST	GNGLQVSGSQ	LVTRIGDGLT	
3fiber		...TTDGSLE	ENIKVNTPLT	KSNHSINLPI	GNGLQIEQNK	LCS.....	
8fiber	301	350
9fiber		
15fiber		
17fiber		
2fiber		YDSSNNMEIK	TGGMRIN..	NNLLILDVDY	PFDAQTKLRL	KLGGQPLYIN	

FIG. 8C-1

5fiber	FDSQGNMQLN	VAGGLRIDSQ	NRRLILDVSY	PFDAQNLNL	RLQGPLFIN
4fiber	FDDKG.....	AAGMRVDGA	N..LILHVAY	PFEAINQLTL	R.....
40-1fiber	FNNTGALQLN	AAGMRVDGA	N..LILHVAY	PFEAINQLTL	R.....
41fiber	FNNTGALQLN	AAGMRVDGA	N..LILHVAY	PFEAINQLTL	R.....
40-2fiber	LGG.SKLIIN	LGPGQLMSNG	A..ITL....	ALDAALPL..Q
12fiber	FDN.GVMKVN	VAGMRTSGG	R..IILDVNY	PFDASNNLNL	RRGLGLIYNQ
3fiber
	351				22/28 400
8fiber	TLVVLTGKGI
9fiber	TLVVLTGKGI
15fiber	TLVVLTGKGL
17fiber	KLVVLTGKGI
2fiber	ASHNLDINYN	RGLYLFNASN	NTKKLEVSIK	KSSGLNFDNT	AIAINAGKGL
5fiber	SAHNLDINYN	KGLYLFNASN	NSKKLEVNL	TAKGLMFDAT	AIAINAGDGL
4fiber	...NIKITLN	RGLHVTGDA	...IESNIS	WAKGIKFEDG	AIAINAGKGS
40-1fiber
41fiber
40-2fiber	YKNN.....QLQLRIGS
12fiber	STNW.....NLTTDIST
3fiber

FIG. 8C-2

23/28

8fiber	401	GTDLSNNGG.	...NICVRVG	E.....	...GGGLS	FNDNGDLVAF	450
9fiber		GTESTDNGG.	...TVCVRVG	E.....	...GGGLS	FNNDGDLVAF	
15fiber		GTDTTDNGG.	...SIRVRVG	E.....	...GGGLS	FNEAGDLVAF	
17fiber		GTENLQNTDG	SSRGIGISVR	A.....	...REGLT	FDNDGYLVAW	
2fiber		EFDTNTSESP	DINPIKTKIG	SGIDYNENGA	MITKLGAGLS	FDNSGAIITIG	
5fiber		EFG..SPNAP	NTNPLKTKIG	HGLEFDSNKA	MVPKLGTLGLS	FDSTGAIITVG	
4fiber		RFGTSSTETG	VNNAYPIQV.KLGSGLS	FDSTGAIMAG	
40-1fiber	LE	NGLEVTNGGK	LVNKLGSGLQ	FDNNGRITIS	
41fiber	LE	NGLEVTSGGK	LVNKLGSGLQ	FDSNGRIAIS	
40-2fiber		ASALIMSGVT	QTLNVNANTS	KGLAIENNS.	LVVKLGNGLR	FDSWGSIAVS	
12fiber		EKGLMFSGN.	...QIALNAG	QGLTFNNGQ.	LRVKLGAGLI	FDSNNNIALG	
3fiber	KLGNGLT	FDSSNSIALK	

FIG. 8D-1

4fiber	TVSVLVVRS.GNLNPI	TGTVSSAQVF	LRFDANGVLL	TEHS.....	
40-1fiber	TITIKGLKGA	LREMNDNA..LSVK	LPFDNQGNLL	NCA.....	
41fiber	TITIKGLKGA	LREMHDNA..LSLK	LPFDNQGNLL	NCA.....	
40-2fiber	TISIKAQKGT	LL..KPTASFISFV	MYFYSDGTWR	KNYPVFDNEG	
12fiber	IVSLVGKGN	LLNIQSTTTTVGVB	LVFDEQGRLI	TSTP.....	
3fiber	YVTLMGASDY	VNTLFKNKNVSINVE	LYFDATGHIL	PDSSSLKTDL	
	551					600
8fiber	..LGKSYWNF	RNQNSIMSTA	YEKAIGFMPN	LVAYPKPTTG	SKKY...ARD	
9fiber	..LGKSYWNF	RNENSIMSTA	YEKAIGFMPN	LVAYPKPTAG	SKKY...ARD	
15fiber	..MDSSYWNY	RSDNSNLSQP	YKKAIGFMPN	KTAYPKQTKP	TNKEISQAKN	
17fiber	..LDSTYWNF	RSDNLTVSEA	YKNAVEFMPN	LVAYPKPTTG	SKKY...ARD	
2fiber	..LKKHYWNF	RNGNSTNANP	YTNAVGFMPN	LLAYPKTQSQ	T.....AKN	
5fiber	..LDPEYWNF	RNGDLTEGTA	YTNAVGFMPN	LSAYPKSHGK	T.....AKS	
4fiber	..TSKKYWGY	KQGDSIDGTP	YTNAVGFMPN	STAYPKTQSS	T.....TKN	
40-1fiber	..LESSTWRY	QETNAVA...	..SNALTFMPN	STVYPRNKTA	D.....PGN	
41fiber	..LESSTWRY	QETNAVA...	..SNALTFMPN	STVYPRNKTA	H.....PGN	
40-2fiber	ILANSATWGY	RQQSANTN.	VSNAVEFMPN	SKRYPNEKGS	E.....VQN	
12fiber	ALVPQASWGY	RQQSVSTNT	VTNGLGFMPN	VSAYPRPNAS	E.....AKS	
3fiber	ELKYKQTADFSARGFMPN	TTAYPFVLPN	AGTH...NEN	


25/28

26/28


601
 8fiber
 9fiber
 15fiber
 17fiber
 2fiber
 5fiber
 4fiber
 40-1fiber
 41fiber
 40-2fiber
 12fiber
 3fiber
 650
 IVYGNIIYLG KPHQ..PVTI KTFNQETG.
 IVYGNIIYLG KPDQ..PVTI KTFNQETG.
 KIVSNVYLG KIDQ..PCVI IISFNEEAD.
 IVYGNIIYLG LAYQ..PVVI KVTFNEEAD.
 NIVSQVYLHG DKTK..PMIL TITLNGTSES
 NIVSQVYLN DKTK..PVTI TITLNGTQET
 NIVGQVYMNG DVSK..PMLL TITLNGTDDT
 MLI..... QISP..NITF SVVYNEINS.
 MLI..... QISP..NITF SVVYNEINS.
 MALTYTFLQG DPNM..AISF QSIYN..HA.
 QMVSLTYLQG DTSK..PITM KVAFNGITS.
 YIFGQCYYKA SDGALFPLEV TVMLNKRLPD
CEYS ITFDFSWAKT
CEYS ITFDFSWAKT
SDYS IVFYFKWYKT
SAYS ITFEFVWNKE
 TETSEVSTYS MSFTWSWESG
 GDTT.PSAYS MSFSWDWSGH
 T.....SAYS MSFSYTWING
GYA FTFKW.SAEP
GYA FTFKW.SAEP
IEGYS LKFTW.RVRN
LNGYS LTFMW.SGLS
 SRTSYVMTFL WSLNAGLAPE

651
 8fiber
 9fiber
 15fiber
 17fiber
 2fiber
 5fiber
 4fiber
 40-1fiber
 41fiber
 40-2fiber
 12fiber
 3fiber
 672
 .YVNVEFET SFTFSYIAQE *.
 .YVNVEFET SFTFSYIAQE *.
 .YENVQFDSS SFNFSYIAQE *.
 .YARVEFET SFTFSYIAQQ *.
 KYTTFATN SYTFSYIAQE ..
 NYINEIFATS SYTFSYIAQE *.
 SYIGATFGAN SYTFSYIAQQ *.
 ...GKPFHPP TAVFCYITEQ *.
 ...GKPFHPP TAVFCYITEQ *.
 ...NERFDIP CCSFSYVTEQ *.
 NYINQPFSTP SCSFSYITQE *.
 T.TQATLITS PFTFSYIRED D*

FIG. 8D-2



28/28



INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 97/21494

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12N15/86 A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C12N A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	P.W. ROELVINK ET AL.: "Comparative analysis of adenovirus fiber-cell interaction: Ad2 and Ad9 utilize the same cellular fiber receptor but use different binding strategies for attachment" JOURNAL OF VIROLOGY, vol. 70, no. 11, November 1996, AMERICAN SOCIETY FOR MICROBIOLOGY US, pages 7614-7621, XP002062100 see page 7620, last paragraph ---	1-13
A	WO 96 26281 A (GENVEC INC ; CORNELL RES FOUNDATION INC (US)) 29 August 1996 see example 7 --- -/--	1,4,6-8, 10,11

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

14 April 1998

Date of mailing of the international search report

123.04.98

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Cupido, M

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 97/21494

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	J. GALL ET AL: "Adenovirus type 5 and 7 capsid chimera: Fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes" JOURNAL OF VIROLOGY., vol. 70, no. 4, April 1996, pages 2116-2123, XP002050655 see the whole document ---	1,4,6-8, 10,11
P,X	WO 97 12986 A (CORNELL RES FOUNDATION INC) 10 April 1997 see page 15, line 1 - line 7 -----	1,2,13

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 97/ 21494

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 11 to 13
because they relate to subject matter not required to be searched by this Authority, namely:
Although these claims are directed to a method of treatment of the human or animal body, the search has been carried out and based on the alleged effects of the adenoviral vector
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No
PCT/US 97/21494

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9626281 A	29-08-96	AU 4980496 A CA 2213343 A EP 0811069 A	11-09-96 29-08-96 10-12-97
-----	-----	-----	-----
WO 9712986 A	10-04-97	NONE	
-----	-----	-----	-----

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.